# Test info

    Code
      info("2015-001314-10")
    Output
      $`A. PROTOCOL INFORMATION`
      $`A. PROTOCOL INFORMATION`$`A.1:Member State Concerned`
      $`A. PROTOCOL INFORMATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`A. PROTOCOL INFORMATION`$`A.2:EudraCT number`
      $`A. PROTOCOL INFORMATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`A. PROTOCOL INFORMATION`$`A.3:Full title of the trial`
      $`A. PROTOCOL INFORMATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`A. PROTOCOL INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`A. PROTOCOL INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`A. PROTOCOL INFORMATION`$`A.4.1:Sponsor's protocol code number`
      $`A. PROTOCOL INFORMATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`A. PROTOCOL INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`A. PROTOCOL INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`A. PROTOCOL INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`A. PROTOCOL INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`A. PROTOCOL INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`A. PROTOCOL INFORMATION`$`B.1.1:Name of Sponsor`
      $`A. PROTOCOL INFORMATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`A. PROTOCOL INFORMATION`$`B.1.3.4:Country`
      $`A. PROTOCOL INFORMATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`A. PROTOCOL INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`
      $`A. PROTOCOL INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`A. PROTOCOL INFORMATION`$`B.4.1:Name of organisation providing support`
      $`A. PROTOCOL INFORMATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`A. PROTOCOL INFORMATION`$`B.4.2:Country`
      $`A. PROTOCOL INFORMATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.1:Name of organisation`
      $`A. PROTOCOL INFORMATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.2:Functional name of contact point`
      $`A. PROTOCOL INFORMATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.3.1:Street Address`
      $`A. PROTOCOL INFORMATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.3.2:Town/ city`
      $`A. PROTOCOL INFORMATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.3.3:Post code`
      $`A. PROTOCOL INFORMATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.3.4:Country`
      $`A. PROTOCOL INFORMATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.4:Telephone number`
      $`A. PROTOCOL INFORMATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.5:Fax number`
      $`A. PROTOCOL INFORMATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`A. PROTOCOL INFORMATION`$`B.5.6:E-mail`
      $`A. PROTOCOL INFORMATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`A. PROTOCOL INFORMATION`$`D.1.2 and D.1.3:IMP Role`
      $`A. PROTOCOL INFORMATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`A. PROTOCOL INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`A. PROTOCOL INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`A. PROTOCOL INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.2.5.1:Orphan drug designation number`
      $`A. PROTOCOL INFORMATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.1:Product name`
      $`A. PROTOCOL INFORMATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.2:Product code`
      $`A. PROTOCOL INFORMATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.4:Pharmaceutical form`
      $`A. PROTOCOL INFORMATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.4.1:Specific paediatric formulation`
      $`A. PROTOCOL INFORMATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.7:Routes of administration for this IMP`
      $`A. PROTOCOL INFORMATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.8:INN - Proposed INN`
      $`A. PROTOCOL INFORMATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.9.2:Current sponsor code`
      $`A. PROTOCOL INFORMATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.9.3:Other descriptive name`
      $`A. PROTOCOL INFORMATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.9.4:EV Substance Code`
      $`A. PROTOCOL INFORMATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.10.1:Concentration unit`
      $`A. PROTOCOL INFORMATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.10.2:Concentration type`
      $`A. PROTOCOL INFORMATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.10.3:Concentration number`
      $`A. PROTOCOL INFORMATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.1:Active substance of chemical origin`
      $`A. PROTOCOL INFORMATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`A. PROTOCOL INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`A. PROTOCOL INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.2:Gene therapy medical product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`A. PROTOCOL INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`A. PROTOCOL INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.7:Plasma derived medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.8:Extractive medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.9:Recombinant medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`A. PROTOCOL INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.11:Herbal medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.12:Homeopathic medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.3.11.13:Another type of medicinal product`
      $`A. PROTOCOL INFORMATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`
      $`A. PROTOCOL INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`
      $`A. PROTOCOL INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`A. PROTOCOL INFORMATION`$`D.8.4:Route of administration of the placebo`
      $`A. PROTOCOL INFORMATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.1:Medical condition(s) being investigated`
      $`A. PROTOCOL INFORMATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.1.1:Medical condition in easily understood language`
      $`A. PROTOCOL INFORMATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.1.2:Therapeutic area`
      $`A. PROTOCOL INFORMATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.2:Version`
      $`A. PROTOCOL INFORMATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.2:Level`
      $`A. PROTOCOL INFORMATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.2:Classification code`
      $`A. PROTOCOL INFORMATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.2:Term`
      $`A. PROTOCOL INFORMATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.2:System Organ Class`
      $`A. PROTOCOL INFORMATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`A. PROTOCOL INFORMATION`$`E.1.3:Condition being studied is a rare disease`
      $`A. PROTOCOL INFORMATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.2.1:Main objective of the trial`
      $`A. PROTOCOL INFORMATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`A. PROTOCOL INFORMATION`$`E.2.2:Secondary objectives of the trial`
      $`A. PROTOCOL INFORMATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`A. PROTOCOL INFORMATION`$`E.2.3:Trial contains a sub-study`
      $`A. PROTOCOL INFORMATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.3:Principal inclusion criteria`
      $`A. PROTOCOL INFORMATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`A. PROTOCOL INFORMATION`$`E.4:Principal exclusion criteria`
      $`A. PROTOCOL INFORMATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`A. PROTOCOL INFORMATION`$`E.5.1:Primary end point(s)`
      $`A. PROTOCOL INFORMATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`A. PROTOCOL INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`A. PROTOCOL INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`A. PROTOCOL INFORMATION`$`E.5.2:Secondary end point(s)`
      $`A. PROTOCOL INFORMATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`A. PROTOCOL INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`A. PROTOCOL INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.1:Diagnosis`
      $`A. PROTOCOL INFORMATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.2:Prophylaxis`
      $`A. PROTOCOL INFORMATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.3:Therapy`
      $`A. PROTOCOL INFORMATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.4:Safety`
      $`A. PROTOCOL INFORMATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.5:Efficacy`
      $`A. PROTOCOL INFORMATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.6:Pharmacokinetic`
      $`A. PROTOCOL INFORMATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.7:Pharmacodynamic`
      $`A. PROTOCOL INFORMATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.8:Bioequivalence`
      $`A. PROTOCOL INFORMATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.9:Dose response`
      $`A. PROTOCOL INFORMATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.10:Pharmacogenetic`
      $`A. PROTOCOL INFORMATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.11:Pharmacogenomic`
      $`A. PROTOCOL INFORMATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.12:Pharmacoeconomic`
      $`A. PROTOCOL INFORMATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.6.13:Others`
      $`A. PROTOCOL INFORMATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.1:Human pharmacology (Phase I)`
      $`A. PROTOCOL INFORMATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.1.1:First administration to humans`
      $`A. PROTOCOL INFORMATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.1.2:Bioequivalence study`
      $`A. PROTOCOL INFORMATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.1.3:Other`
      $`A. PROTOCOL INFORMATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.1.3.1:Other trial type description`
      $`A. PROTOCOL INFORMATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`A. PROTOCOL INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`A. PROTOCOL INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`
      $`A. PROTOCOL INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1:Controlled`
      $`A. PROTOCOL INFORMATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.1:Randomised`
      $`A. PROTOCOL INFORMATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.2:Open`
      $`A. PROTOCOL INFORMATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.3:Single blind`
      $`A. PROTOCOL INFORMATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.4:Double blind`
      $`A. PROTOCOL INFORMATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.5:Parallel group`
      $`A. PROTOCOL INFORMATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.6:Cross over`
      $`A. PROTOCOL INFORMATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.1.7:Other`
      $`A. PROTOCOL INFORMATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.2.1:Other medicinal product(s)`
      $`A. PROTOCOL INFORMATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.2.2:Placebo`
      $`A. PROTOCOL INFORMATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.2.3:Other`
      $`A. PROTOCOL INFORMATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`
      $`A. PROTOCOL INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`
      $`A. PROTOCOL INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`A. PROTOCOL INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`A. PROTOCOL INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.5:The trial involves multiple Member States`
      $`A. PROTOCOL INFORMATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`A. PROTOCOL INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`A. PROTOCOL INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`A. PROTOCOL INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`A. PROTOCOL INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.7:Trial has a data monitoring committee`
      $`A. PROTOCOL INFORMATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`A. PROTOCOL INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned years`
      $`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned months`
      $`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned days`
      $`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`
      $`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`
      $`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`
      $`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1:Trial has subjects under 18`
      $`A. PROTOCOL INFORMATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1.1:In Utero`
      $`A. PROTOCOL INFORMATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`A. PROTOCOL INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1.3:Newborns (0-27 days)`
      $`A. PROTOCOL INFORMATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`A. PROTOCOL INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1.5:Children (2-11years)`
      $`A. PROTOCOL INFORMATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`
      $`A. PROTOCOL INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.2:Adults (18-64 years)`
      $`A. PROTOCOL INFORMATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.2.1:Number of subjects for this age range:`
      $`A. PROTOCOL INFORMATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.3:Elderly (>=65 years)`
      $`A. PROTOCOL INFORMATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.1.3.1:Number of subjects for this age range:`
      $`A. PROTOCOL INFORMATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`A. PROTOCOL INFORMATION`$`F.2.1:Female`
      $`A. PROTOCOL INFORMATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.2.2:Male`
      $`A. PROTOCOL INFORMATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.1:Healthy volunteers`
      $`A. PROTOCOL INFORMATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.2:Patients`
      $`A. PROTOCOL INFORMATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3:Specific vulnerable populations`
      $`A. PROTOCOL INFORMATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`A. PROTOCOL INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`A. PROTOCOL INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.3:Pregnant women`
      $`A. PROTOCOL INFORMATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.4:Nursing women`
      $`A. PROTOCOL INFORMATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.5:Emergency situation`
      $`A. PROTOCOL INFORMATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`A. PROTOCOL INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.3.3.7:Others`
      $`A. PROTOCOL INFORMATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`A. PROTOCOL INFORMATION`$`F.4.1:In the member state`
      $`A. PROTOCOL INFORMATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`A. PROTOCOL INFORMATION`$`F.4.2.1:In the EEA`
      $`A. PROTOCOL INFORMATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`A. PROTOCOL INFORMATION`$`F.4.2.2:In the whole clinical trial`
      $`A. PROTOCOL INFORMATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`A. PROTOCOL INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`A. PROTOCOL INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`A. PROTOCOL INFORMATION`$`N.:Competent Authority Decision`
      $`A. PROTOCOL INFORMATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`A. PROTOCOL INFORMATION`$`N.:Date of Competent Authority Decision`
      $`A. PROTOCOL INFORMATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion of the trial application`
      $`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`A. PROTOCOL INFORMATION`$`N.:Date of Ethics Committee Opinion`
      $`A. PROTOCOL INFORMATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`A. PROTOCOL INFORMATION`$`P.:End of Trial Status`
      $`A. PROTOCOL INFORMATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`B. SPONSOR INFORMATION`
      $`B. SPONSOR INFORMATION`$`A.1:Member State Concerned`
      $`B. SPONSOR INFORMATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`B. SPONSOR INFORMATION`$`A.2:EudraCT number`
      $`B. SPONSOR INFORMATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`B. SPONSOR INFORMATION`$`A.3:Full title of the trial`
      $`B. SPONSOR INFORMATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`B. SPONSOR INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`B. SPONSOR INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`B. SPONSOR INFORMATION`$`A.4.1:Sponsor's protocol code number`
      $`B. SPONSOR INFORMATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`B. SPONSOR INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`B. SPONSOR INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`B. SPONSOR INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`B. SPONSOR INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`B. SPONSOR INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`B. SPONSOR INFORMATION`$`B.1.1:Name of Sponsor`
      $`B. SPONSOR INFORMATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`B. SPONSOR INFORMATION`$`B.1.3.4:Country`
      $`B. SPONSOR INFORMATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`B. SPONSOR INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`
      $`B. SPONSOR INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`B. SPONSOR INFORMATION`$`B.4.1:Name of organisation providing support`
      $`B. SPONSOR INFORMATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`B. SPONSOR INFORMATION`$`B.4.2:Country`
      $`B. SPONSOR INFORMATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.1:Name of organisation`
      $`B. SPONSOR INFORMATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.2:Functional name of contact point`
      $`B. SPONSOR INFORMATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.3.1:Street Address`
      $`B. SPONSOR INFORMATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.3.2:Town/ city`
      $`B. SPONSOR INFORMATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.3.3:Post code`
      $`B. SPONSOR INFORMATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.3.4:Country`
      $`B. SPONSOR INFORMATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.4:Telephone number`
      $`B. SPONSOR INFORMATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.5:Fax number`
      $`B. SPONSOR INFORMATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`B. SPONSOR INFORMATION`$`B.5.6:E-mail`
      $`B. SPONSOR INFORMATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`B. SPONSOR INFORMATION`$`D.1.2 and D.1.3:IMP Role`
      $`B. SPONSOR INFORMATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`B. SPONSOR INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`B. SPONSOR INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`B. SPONSOR INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.2.5.1:Orphan drug designation number`
      $`B. SPONSOR INFORMATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`B. SPONSOR INFORMATION`$`D.3.1:Product name`
      $`B. SPONSOR INFORMATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.2:Product code`
      $`B. SPONSOR INFORMATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.4:Pharmaceutical form`
      $`B. SPONSOR INFORMATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.4.1:Specific paediatric formulation`
      $`B. SPONSOR INFORMATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.7:Routes of administration for this IMP`
      $`B. SPONSOR INFORMATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.8:INN - Proposed INN`
      $`B. SPONSOR INFORMATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.9.2:Current sponsor code`
      $`B. SPONSOR INFORMATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.9.3:Other descriptive name`
      $`B. SPONSOR INFORMATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.9.4:EV Substance Code`
      $`B. SPONSOR INFORMATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.10.1:Concentration unit`
      $`B. SPONSOR INFORMATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.10.2:Concentration type`
      $`B. SPONSOR INFORMATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.10.3:Concentration number`
      $`B. SPONSOR INFORMATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.1:Active substance of chemical origin`
      $`B. SPONSOR INFORMATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`B. SPONSOR INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`B. SPONSOR INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.3.2:Gene therapy medical product`
      $`B. SPONSOR INFORMATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`
      $`B. SPONSOR INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`B. SPONSOR INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`B. SPONSOR INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`B. SPONSOR INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`B. SPONSOR INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.7:Plasma derived medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.8:Extractive medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.9:Recombinant medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`B. SPONSOR INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.11:Herbal medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.12:Homeopathic medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.3.11.13:Another type of medicinal product`
      $`B. SPONSOR INFORMATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`
      $`B. SPONSOR INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`
      $`B. SPONSOR INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`B. SPONSOR INFORMATION`$`D.8.4:Route of administration of the placebo`
      $`B. SPONSOR INFORMATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.1:Medical condition(s) being investigated`
      $`B. SPONSOR INFORMATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.1.1:Medical condition in easily understood language`
      $`B. SPONSOR INFORMATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.1.2:Therapeutic area`
      $`B. SPONSOR INFORMATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.2:Version`
      $`B. SPONSOR INFORMATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.2:Level`
      $`B. SPONSOR INFORMATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.2:Classification code`
      $`B. SPONSOR INFORMATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.2:Term`
      $`B. SPONSOR INFORMATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.2:System Organ Class`
      $`B. SPONSOR INFORMATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`B. SPONSOR INFORMATION`$`E.1.3:Condition being studied is a rare disease`
      $`B. SPONSOR INFORMATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.2.1:Main objective of the trial`
      $`B. SPONSOR INFORMATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`B. SPONSOR INFORMATION`$`E.2.2:Secondary objectives of the trial`
      $`B. SPONSOR INFORMATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`B. SPONSOR INFORMATION`$`E.2.3:Trial contains a sub-study`
      $`B. SPONSOR INFORMATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.3:Principal inclusion criteria`
      $`B. SPONSOR INFORMATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`B. SPONSOR INFORMATION`$`E.4:Principal exclusion criteria`
      $`B. SPONSOR INFORMATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`B. SPONSOR INFORMATION`$`E.5.1:Primary end point(s)`
      $`B. SPONSOR INFORMATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`B. SPONSOR INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`B. SPONSOR INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`B. SPONSOR INFORMATION`$`E.5.2:Secondary end point(s)`
      $`B. SPONSOR INFORMATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`B. SPONSOR INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`B. SPONSOR INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.1:Diagnosis`
      $`B. SPONSOR INFORMATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.2:Prophylaxis`
      $`B. SPONSOR INFORMATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.3:Therapy`
      $`B. SPONSOR INFORMATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.4:Safety`
      $`B. SPONSOR INFORMATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.5:Efficacy`
      $`B. SPONSOR INFORMATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.6:Pharmacokinetic`
      $`B. SPONSOR INFORMATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.7:Pharmacodynamic`
      $`B. SPONSOR INFORMATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.8:Bioequivalence`
      $`B. SPONSOR INFORMATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.9:Dose response`
      $`B. SPONSOR INFORMATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.10:Pharmacogenetic`
      $`B. SPONSOR INFORMATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.11:Pharmacogenomic`
      $`B. SPONSOR INFORMATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.12:Pharmacoeconomic`
      $`B. SPONSOR INFORMATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.6.13:Others`
      $`B. SPONSOR INFORMATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.1:Human pharmacology (Phase I)`
      $`B. SPONSOR INFORMATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.1.1:First administration to humans`
      $`B. SPONSOR INFORMATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.1.2:Bioequivalence study`
      $`B. SPONSOR INFORMATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.1.3:Other`
      $`B. SPONSOR INFORMATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.1.3.1:Other trial type description`
      $`B. SPONSOR INFORMATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`B. SPONSOR INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`B. SPONSOR INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`B. SPONSOR INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`
      $`B. SPONSOR INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1:Controlled`
      $`B. SPONSOR INFORMATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.1:Randomised`
      $`B. SPONSOR INFORMATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.2:Open`
      $`B. SPONSOR INFORMATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.3:Single blind`
      $`B. SPONSOR INFORMATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.4:Double blind`
      $`B. SPONSOR INFORMATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.5:Parallel group`
      $`B. SPONSOR INFORMATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.6:Cross over`
      $`B. SPONSOR INFORMATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.1.7:Other`
      $`B. SPONSOR INFORMATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.2.1:Other medicinal product(s)`
      $`B. SPONSOR INFORMATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.2.2:Placebo`
      $`B. SPONSOR INFORMATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.2.3:Other`
      $`B. SPONSOR INFORMATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`
      $`B. SPONSOR INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`
      $`B. SPONSOR INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`B. SPONSOR INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`B. SPONSOR INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.5:The trial involves multiple Member States`
      $`B. SPONSOR INFORMATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`B. SPONSOR INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`B. SPONSOR INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`B. SPONSOR INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`B. SPONSOR INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.7:Trial has a data monitoring committee`
      $`B. SPONSOR INFORMATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`B. SPONSOR INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned years`
      $`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned months`
      $`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned days`
      $`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`
      $`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`
      $`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`
      $`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1:Trial has subjects under 18`
      $`B. SPONSOR INFORMATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1.1:In Utero`
      $`B. SPONSOR INFORMATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`B. SPONSOR INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1.3:Newborns (0-27 days)`
      $`B. SPONSOR INFORMATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`B. SPONSOR INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1.5:Children (2-11years)`
      $`B. SPONSOR INFORMATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`
      $`B. SPONSOR INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.2:Adults (18-64 years)`
      $`B. SPONSOR INFORMATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.2.1:Number of subjects for this age range:`
      $`B. SPONSOR INFORMATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.3:Elderly (>=65 years)`
      $`B. SPONSOR INFORMATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.1.3.1:Number of subjects for this age range:`
      $`B. SPONSOR INFORMATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`B. SPONSOR INFORMATION`$`F.2.1:Female`
      $`B. SPONSOR INFORMATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.2.2:Male`
      $`B. SPONSOR INFORMATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.1:Healthy volunteers`
      $`B. SPONSOR INFORMATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.2:Patients`
      $`B. SPONSOR INFORMATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3:Specific vulnerable populations`
      $`B. SPONSOR INFORMATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`B. SPONSOR INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`B. SPONSOR INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.3:Pregnant women`
      $`B. SPONSOR INFORMATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.4:Nursing women`
      $`B. SPONSOR INFORMATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.5:Emergency situation`
      $`B. SPONSOR INFORMATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`B. SPONSOR INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.3.3.7:Others`
      $`B. SPONSOR INFORMATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`B. SPONSOR INFORMATION`$`F.4.1:In the member state`
      $`B. SPONSOR INFORMATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`B. SPONSOR INFORMATION`$`F.4.2.1:In the EEA`
      $`B. SPONSOR INFORMATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`B. SPONSOR INFORMATION`$`F.4.2.2:In the whole clinical trial`
      $`B. SPONSOR INFORMATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`B. SPONSOR INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`B. SPONSOR INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`B. SPONSOR INFORMATION`$`N.:Competent Authority Decision`
      $`B. SPONSOR INFORMATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`B. SPONSOR INFORMATION`$`N.:Date of Competent Authority Decision`
      $`B. SPONSOR INFORMATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion of the trial application`
      $`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`B. SPONSOR INFORMATION`$`N.:Date of Ethics Committee Opinion`
      $`B. SPONSOR INFORMATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`B. SPONSOR INFORMATION`$`P.:End of Trial Status`
      $`B. SPONSOR INFORMATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`C. APPLICANT IDENTIFICATION`
      $`C. APPLICANT IDENTIFICATION`$`A.1:Member State Concerned`
      $`C. APPLICANT IDENTIFICATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.2:EudraCT number`
      $`C. APPLICANT IDENTIFICATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.3:Full title of the trial`
      $`C. APPLICANT IDENTIFICATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`C. APPLICANT IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`
      $`C. APPLICANT IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`C. APPLICANT IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`C. APPLICANT IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`C. APPLICANT IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.1.1:Name of Sponsor`
      $`C. APPLICANT IDENTIFICATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.1.3.4:Country`
      $`C. APPLICANT IDENTIFICATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`
      $`C. APPLICANT IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.4.1:Name of organisation providing support`
      $`C. APPLICANT IDENTIFICATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.4.2:Country`
      $`C. APPLICANT IDENTIFICATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.1:Name of organisation`
      $`C. APPLICANT IDENTIFICATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.2:Functional name of contact point`
      $`C. APPLICANT IDENTIFICATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.1:Street Address`
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.2:Town/ city`
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.3:Post code`
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.4:Country`
      $`C. APPLICANT IDENTIFICATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.4:Telephone number`
      $`C. APPLICANT IDENTIFICATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.5:Fax number`
      $`C. APPLICANT IDENTIFICATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`C. APPLICANT IDENTIFICATION`$`B.5.6:E-mail`
      $`C. APPLICANT IDENTIFICATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`
      $`C. APPLICANT IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`C. APPLICANT IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`C. APPLICANT IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`
      $`C. APPLICANT IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.1:Product name`
      $`C. APPLICANT IDENTIFICATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.2:Product code`
      $`C. APPLICANT IDENTIFICATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.4:Pharmaceutical form`
      $`C. APPLICANT IDENTIFICATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`
      $`C. APPLICANT IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`
      $`C. APPLICANT IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.8:INN - Proposed INN`
      $`C. APPLICANT IDENTIFICATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.9.2:Current sponsor code`
      $`C. APPLICANT IDENTIFICATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.9.3:Other descriptive name`
      $`C. APPLICANT IDENTIFICATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.9.4:EV Substance Code`
      $`C. APPLICANT IDENTIFICATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.10.1:Concentration unit`
      $`C. APPLICANT IDENTIFICATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.10.2:Concentration type`
      $`C. APPLICANT IDENTIFICATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.10.3:Concentration number`
      $`C. APPLICANT IDENTIFICATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`
      $`C. APPLICANT IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`
      $`C. APPLICANT IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`
      $`C. APPLICANT IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`C. APPLICANT IDENTIFICATION`$`D.8.4:Route of administration of the placebo`
      $`C. APPLICANT IDENTIFICATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`
      $`C. APPLICANT IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`
      $`C. APPLICANT IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.1.2:Therapeutic area`
      $`C. APPLICANT IDENTIFICATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Version`
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Level`
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Classification code`
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Term`
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:System Organ Class`
      $`C. APPLICANT IDENTIFICATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`
      $`C. APPLICANT IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.2.1:Main objective of the trial`
      $`C. APPLICANT IDENTIFICATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`
      $`C. APPLICANT IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.2.3:Trial contains a sub-study`
      $`C. APPLICANT IDENTIFICATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.3:Principal inclusion criteria`
      $`C. APPLICANT IDENTIFICATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.4:Principal exclusion criteria`
      $`C. APPLICANT IDENTIFICATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.5.1:Primary end point(s)`
      $`C. APPLICANT IDENTIFICATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`C. APPLICANT IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.5.2:Secondary end point(s)`
      $`C. APPLICANT IDENTIFICATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`C. APPLICANT IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.1:Diagnosis`
      $`C. APPLICANT IDENTIFICATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.2:Prophylaxis`
      $`C. APPLICANT IDENTIFICATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.3:Therapy`
      $`C. APPLICANT IDENTIFICATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.4:Safety`
      $`C. APPLICANT IDENTIFICATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.5:Efficacy`
      $`C. APPLICANT IDENTIFICATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.6:Pharmacokinetic`
      $`C. APPLICANT IDENTIFICATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.7:Pharmacodynamic`
      $`C. APPLICANT IDENTIFICATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.8:Bioequivalence`
      $`C. APPLICANT IDENTIFICATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.9:Dose response`
      $`C. APPLICANT IDENTIFICATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.10:Pharmacogenetic`
      $`C. APPLICANT IDENTIFICATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.11:Pharmacogenomic`
      $`C. APPLICANT IDENTIFICATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.12:Pharmacoeconomic`
      $`C. APPLICANT IDENTIFICATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.6.13:Others`
      $`C. APPLICANT IDENTIFICATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`
      $`C. APPLICANT IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.1:First administration to humans`
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.2:Bioequivalence study`
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.3:Other`
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.3.1:Other trial type description`
      $`C. APPLICANT IDENTIFICATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`C. APPLICANT IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`C. APPLICANT IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`
      $`C. APPLICANT IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1:Controlled`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.1:Randomised`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.2:Open`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.3:Single blind`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.4:Double blind`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.5:Parallel group`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.6:Cross over`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.7:Other`
      $`C. APPLICANT IDENTIFICATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.2:Placebo`
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.3:Other`
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`
      $`C. APPLICANT IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`
      $`C. APPLICANT IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`C. APPLICANT IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`C. APPLICANT IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`
      $`C. APPLICANT IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`C. APPLICANT IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`C. APPLICANT IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`C. APPLICANT IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`C. APPLICANT IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`
      $`C. APPLICANT IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`C. APPLICANT IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`
      $`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1:Trial has subjects under 18`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.1:In Utero`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.5:Children (2-11years)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.2:Adults (18-64 years)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`
      $`C. APPLICANT IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`
      $`C. APPLICANT IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`
      $`C. APPLICANT IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.2.1:Female`
      $`C. APPLICANT IDENTIFICATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.2.2:Male`
      $`C. APPLICANT IDENTIFICATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.1:Healthy volunteers`
      $`C. APPLICANT IDENTIFICATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.2:Patients`
      $`C. APPLICANT IDENTIFICATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3:Specific vulnerable populations`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.3:Pregnant women`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.4:Nursing women`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.5:Emergency situation`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.7:Others`
      $`C. APPLICANT IDENTIFICATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.4.1:In the member state`
      $`C. APPLICANT IDENTIFICATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.4.2.1:In the EEA`
      $`C. APPLICANT IDENTIFICATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`
      $`C. APPLICANT IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`C. APPLICANT IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`C. APPLICANT IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`C. APPLICANT IDENTIFICATION`$`N.:Competent Authority Decision`
      $`C. APPLICANT IDENTIFICATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`C. APPLICANT IDENTIFICATION`$`N.:Date of Competent Authority Decision`
      $`C. APPLICANT IDENTIFICATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`
      $`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`C. APPLICANT IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`
      $`C. APPLICANT IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`C. APPLICANT IDENTIFICATION`$`P.:End of Trial Status`
      $`C. APPLICANT IDENTIFICATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`D. IMP IDENTIFICATION`
      $`D. IMP IDENTIFICATION`$`A.1:Member State Concerned`
      $`D. IMP IDENTIFICATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`D. IMP IDENTIFICATION`$`A.2:EudraCT number`
      $`D. IMP IDENTIFICATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`D. IMP IDENTIFICATION`$`A.3:Full title of the trial`
      $`D. IMP IDENTIFICATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`D. IMP IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`D. IMP IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`D. IMP IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`
      $`D. IMP IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`D. IMP IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`D. IMP IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`D. IMP IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`D. IMP IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`D. IMP IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`D. IMP IDENTIFICATION`$`B.1.1:Name of Sponsor`
      $`D. IMP IDENTIFICATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`D. IMP IDENTIFICATION`$`B.1.3.4:Country`
      $`D. IMP IDENTIFICATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`D. IMP IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`
      $`D. IMP IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`D. IMP IDENTIFICATION`$`B.4.1:Name of organisation providing support`
      $`D. IMP IDENTIFICATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`D. IMP IDENTIFICATION`$`B.4.2:Country`
      $`D. IMP IDENTIFICATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.1:Name of organisation`
      $`D. IMP IDENTIFICATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.2:Functional name of contact point`
      $`D. IMP IDENTIFICATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.3.1:Street Address`
      $`D. IMP IDENTIFICATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.3.2:Town/ city`
      $`D. IMP IDENTIFICATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.3.3:Post code`
      $`D. IMP IDENTIFICATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.3.4:Country`
      $`D. IMP IDENTIFICATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.4:Telephone number`
      $`D. IMP IDENTIFICATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.5:Fax number`
      $`D. IMP IDENTIFICATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`D. IMP IDENTIFICATION`$`B.5.6:E-mail`
      $`D. IMP IDENTIFICATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`D. IMP IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`
      $`D. IMP IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`D. IMP IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`D. IMP IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`D. IMP IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`
      $`D. IMP IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`D. IMP IDENTIFICATION`$`D.3.1:Product name`
      $`D. IMP IDENTIFICATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.2:Product code`
      $`D. IMP IDENTIFICATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.4:Pharmaceutical form`
      $`D. IMP IDENTIFICATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`
      $`D. IMP IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`
      $`D. IMP IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.8:INN - Proposed INN`
      $`D. IMP IDENTIFICATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.9.2:Current sponsor code`
      $`D. IMP IDENTIFICATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.9.3:Other descriptive name`
      $`D. IMP IDENTIFICATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.9.4:EV Substance Code`
      $`D. IMP IDENTIFICATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.10.1:Concentration unit`
      $`D. IMP IDENTIFICATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.10.2:Concentration type`
      $`D. IMP IDENTIFICATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.10.3:Concentration number`
      $`D. IMP IDENTIFICATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`
      $`D. IMP IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`D. IMP IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`D. IMP IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`
      $`D. IMP IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`
      $`D. IMP IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`D. IMP IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`D. IMP IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`D. IMP IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`D. IMP IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`D. IMP IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`
      $`D. IMP IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`
      $`D. IMP IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`
      $`D. IMP IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`D. IMP IDENTIFICATION`$`D.8.4:Route of administration of the placebo`
      $`D. IMP IDENTIFICATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`
      $`D. IMP IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`
      $`D. IMP IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.1.2:Therapeutic area`
      $`D. IMP IDENTIFICATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.2:Version`
      $`D. IMP IDENTIFICATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.2:Level`
      $`D. IMP IDENTIFICATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.2:Classification code`
      $`D. IMP IDENTIFICATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.2:Term`
      $`D. IMP IDENTIFICATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.2:System Organ Class`
      $`D. IMP IDENTIFICATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`D. IMP IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`
      $`D. IMP IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.2.1:Main objective of the trial`
      $`D. IMP IDENTIFICATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`D. IMP IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`
      $`D. IMP IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`D. IMP IDENTIFICATION`$`E.2.3:Trial contains a sub-study`
      $`D. IMP IDENTIFICATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.3:Principal inclusion criteria`
      $`D. IMP IDENTIFICATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`D. IMP IDENTIFICATION`$`E.4:Principal exclusion criteria`
      $`D. IMP IDENTIFICATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`D. IMP IDENTIFICATION`$`E.5.1:Primary end point(s)`
      $`D. IMP IDENTIFICATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`D. IMP IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`D. IMP IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`D. IMP IDENTIFICATION`$`E.5.2:Secondary end point(s)`
      $`D. IMP IDENTIFICATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`D. IMP IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`D. IMP IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.1:Diagnosis`
      $`D. IMP IDENTIFICATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.2:Prophylaxis`
      $`D. IMP IDENTIFICATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.3:Therapy`
      $`D. IMP IDENTIFICATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.4:Safety`
      $`D. IMP IDENTIFICATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.5:Efficacy`
      $`D. IMP IDENTIFICATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.6:Pharmacokinetic`
      $`D. IMP IDENTIFICATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.7:Pharmacodynamic`
      $`D. IMP IDENTIFICATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.8:Bioequivalence`
      $`D. IMP IDENTIFICATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.9:Dose response`
      $`D. IMP IDENTIFICATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.10:Pharmacogenetic`
      $`D. IMP IDENTIFICATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.11:Pharmacogenomic`
      $`D. IMP IDENTIFICATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.12:Pharmacoeconomic`
      $`D. IMP IDENTIFICATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.6.13:Others`
      $`D. IMP IDENTIFICATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`
      $`D. IMP IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.1.1:First administration to humans`
      $`D. IMP IDENTIFICATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.1.2:Bioequivalence study`
      $`D. IMP IDENTIFICATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.1.3:Other`
      $`D. IMP IDENTIFICATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.1.3.1:Other trial type description`
      $`D. IMP IDENTIFICATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`D. IMP IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`D. IMP IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`D. IMP IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`
      $`D. IMP IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1:Controlled`
      $`D. IMP IDENTIFICATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.1:Randomised`
      $`D. IMP IDENTIFICATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.2:Open`
      $`D. IMP IDENTIFICATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.3:Single blind`
      $`D. IMP IDENTIFICATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.4:Double blind`
      $`D. IMP IDENTIFICATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.5:Parallel group`
      $`D. IMP IDENTIFICATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.6:Cross over`
      $`D. IMP IDENTIFICATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.1.7:Other`
      $`D. IMP IDENTIFICATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`
      $`D. IMP IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.2.2:Placebo`
      $`D. IMP IDENTIFICATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.2.3:Other`
      $`D. IMP IDENTIFICATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`
      $`D. IMP IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`
      $`D. IMP IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`D. IMP IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`D. IMP IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`
      $`D. IMP IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`D. IMP IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`D. IMP IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`D. IMP IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`D. IMP IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`
      $`D. IMP IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`D. IMP IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`
      $`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`
      $`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`
      $`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`
      $`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`
      $`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`
      $`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1:Trial has subjects under 18`
      $`D. IMP IDENTIFICATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1.1:In Utero`
      $`D. IMP IDENTIFICATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`D. IMP IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`
      $`D. IMP IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`D. IMP IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1.5:Children (2-11years)`
      $`D. IMP IDENTIFICATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`
      $`D. IMP IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.2:Adults (18-64 years)`
      $`D. IMP IDENTIFICATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`
      $`D. IMP IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`
      $`D. IMP IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`
      $`D. IMP IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`D. IMP IDENTIFICATION`$`F.2.1:Female`
      $`D. IMP IDENTIFICATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.2.2:Male`
      $`D. IMP IDENTIFICATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.1:Healthy volunteers`
      $`D. IMP IDENTIFICATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.2:Patients`
      $`D. IMP IDENTIFICATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3:Specific vulnerable populations`
      $`D. IMP IDENTIFICATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`D. IMP IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`D. IMP IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.3:Pregnant women`
      $`D. IMP IDENTIFICATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.4:Nursing women`
      $`D. IMP IDENTIFICATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.5:Emergency situation`
      $`D. IMP IDENTIFICATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`D. IMP IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.3.3.7:Others`
      $`D. IMP IDENTIFICATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`D. IMP IDENTIFICATION`$`F.4.1:In the member state`
      $`D. IMP IDENTIFICATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`D. IMP IDENTIFICATION`$`F.4.2.1:In the EEA`
      $`D. IMP IDENTIFICATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`D. IMP IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`
      $`D. IMP IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`D. IMP IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`D. IMP IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`D. IMP IDENTIFICATION`$`N.:Competent Authority Decision`
      $`D. IMP IDENTIFICATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`D. IMP IDENTIFICATION`$`N.:Date of Competent Authority Decision`
      $`D. IMP IDENTIFICATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`
      $`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`D. IMP IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`
      $`D. IMP IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`D. IMP IDENTIFICATION`$`P.:End of Trial Status`
      $`D. IMP IDENTIFICATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.1:Member State Concerned`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.2:EudraCT number`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.3:Full title of the trial`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.4.1:Sponsor's protocol code number`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.1:Name of Sponsor`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.3.4:Country`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.1:Name of organisation providing support`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.2:Country`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.1:Name of organisation`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.2:Functional name of contact point`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.1:Street Address`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.2:Town/ city`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.3:Post code`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.4:Country`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.4:Telephone number`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.5:Fax number`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.6:E-mail`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.1.2 and D.1.3:IMP Role`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5.1:Orphan drug designation number`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.1:Product name`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.2:Product code`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4:Pharmaceutical form`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4.1:Specific paediatric formulation`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.7:Routes of administration for this IMP`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.8:INN - Proposed INN`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.2:Current sponsor code`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.3:Other descriptive name`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.4:EV Substance Code`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.1:Concentration unit`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.2:Concentration type`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.3:Concentration number`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.1:Active substance of chemical origin`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.8:Extractive medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.9:Recombinant medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.11:Herbal medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.13:Another type of medicinal product`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.4:Route of administration of the placebo`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1:Medical condition(s) being investigated`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.2:Therapeutic area`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Version`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Level`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Classification code`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Term`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:System Organ Class`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.3:Condition being studied is a rare disease`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.1:Main objective of the trial`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.2:Secondary objectives of the trial`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.3:Trial contains a sub-study`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.3:Principal inclusion criteria`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.4:Principal exclusion criteria`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1:Primary end point(s)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2:Secondary end point(s)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.1:Diagnosis`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.2:Prophylaxis`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.3:Therapy`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.4:Safety`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.5:Efficacy`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.6:Pharmacokinetic`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.7:Pharmacodynamic`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.8:Bioequivalence`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.9:Dose response`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.10:Pharmacogenetic`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.11:Pharmacogenomic`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.12:Pharmacoeconomic`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.13:Others`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.1:First administration to humans`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.2:Bioequivalence study`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3:Other`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3.1:Other trial type description`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1:Controlled`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.1:Randomised`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.2:Open`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.3:Single blind`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.4:Double blind`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.5:Parallel group`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.6:Cross over`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.7:Other`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.1:Other medicinal product(s)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.2:Placebo`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.3:Other`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5:The trial involves multiple Member States`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.7:Trial has a data monitoring committee`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned years`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned months`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned days`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1:Trial has subjects under 18`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.1:In Utero`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.5:Children (2-11years)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2:Adults (18-64 years)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3:Elderly (>=65 years)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.1:Female`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.2:Male`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.1:Healthy volunteers`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.2:Patients`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3:Specific vulnerable populations`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.3:Pregnant women`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.4:Nursing women`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.5:Emergency situation`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.7:Others`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.1:In the member state`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.1:In the EEA`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.2:In the whole clinical trial`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Competent Authority Decision`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Competent Authority Decision`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Ethics Committee Opinion`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`E. GENERAL INFORMATION ON THE TRIAL`$`P.:End of Trial Status`
      $`E. GENERAL INFORMATION ON THE TRIAL`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.1:Member State Concerned`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.2:EudraCT number`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.3:Full title of the trial`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.4.1:Sponsor's protocol code number`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`F. POPULATION OF TRIAL SUBJECTS`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.1.1:Name of Sponsor`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.1.3.4:Country`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.3.1 and B.3.2:Status of the sponsor`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.4.1:Name of organisation providing support`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.4.2:Country`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.1:Name of organisation`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.2:Functional name of contact point`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.1:Street Address`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.2:Town/ city`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.3:Post code`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.4:Country`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.4:Telephone number`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.5:Fax number`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.6:E-mail`
      $`F. POPULATION OF TRIAL SUBJECTS`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.1.2 and D.1.3:IMP Role`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5.1:Orphan drug designation number`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.1:Product name`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.2:Product code`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4:Pharmaceutical form`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4.1:Specific paediatric formulation`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.7:Routes of administration for this IMP`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.8:INN - Proposed INN`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.2:Current sponsor code`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.3:Other descriptive name`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.4:EV Substance Code`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.1:Concentration unit`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.2:Concentration type`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.3:Concentration number`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.1:Active substance of chemical origin`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.2:Gene therapy medical product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.3:Tissue Engineered Product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.7:Plasma derived medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.8:Extractive medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.9:Recombinant medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.11:Herbal medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.12:Homeopathic medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.13:Another type of medicinal product`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.8.1:Is a Placebo used in this Trial?`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.8.3:Pharmaceutical form of the placebo`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.8.4:Route of administration of the placebo`
      $`F. POPULATION OF TRIAL SUBJECTS`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1:Medical condition(s) being investigated`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.1:Medical condition in easily understood language`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.2:Therapeutic area`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Version`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Level`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Classification code`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Term`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:System Organ Class`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.3:Condition being studied is a rare disease`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.2.1:Main objective of the trial`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.2.2:Secondary objectives of the trial`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.2.3:Trial contains a sub-study`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.3:Principal inclusion criteria`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.4:Principal exclusion criteria`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1:Primary end point(s)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2:Secondary end point(s)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.1:Diagnosis`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.2:Prophylaxis`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.3:Therapy`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.4:Safety`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.5:Efficacy`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.6:Pharmacokinetic`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.7:Pharmacodynamic`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.8:Bioequivalence`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.9:Dose response`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.10:Pharmacogenetic`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.11:Pharmacogenomic`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.12:Pharmacoeconomic`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.13:Others`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1:Human pharmacology (Phase I)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.1:First administration to humans`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.2:Bioequivalence study`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3:Other`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3.1:Other trial type description`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.4:Therapeutic use (Phase IV)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1:Controlled`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.1:Randomised`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.2:Open`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.3:Single blind`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.4:Double blind`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.5:Parallel group`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.6:Cross over`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.7:Other`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.1:Other medicinal product(s)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.2:Placebo`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.3:Other`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.4:Number of treatment arms in the trial`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.3:The trial involves single site in the Member State concerned`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5:The trial involves multiple Member States`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.7:Trial has a data monitoring committee`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned years`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned months`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned days`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial years`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial months`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial days`
      $`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1:Trial has subjects under 18`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.1:In Utero`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.3:Newborns (0-27 days)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.5:Children (2-11years)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.6:Adolescents (12-17 years)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2:Adults (18-64 years)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2.1:Number of subjects for this age range:`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3:Elderly (>=65 years)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3.1:Number of subjects for this age range:`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.2.1:Female`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.2.2:Male`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.1:Healthy volunteers`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.2:Patients`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3:Specific vulnerable populations`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.3:Pregnant women`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.4:Nursing women`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.5:Emergency situation`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.7:Others`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.4.1:In the member state`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.1:In the EEA`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.2:In the whole clinical trial`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`F. POPULATION OF TRIAL SUBJECTS`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Competent Authority Decision`
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Competent Authority Decision`
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion of the trial application`
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Ethics Committee Opinion`
      $`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`F. POPULATION OF TRIAL SUBJECTS`$`P.:End of Trial Status`
      $`F. POPULATION OF TRIAL SUBJECTS`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.1:Member State Concerned`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.2:EudraCT number`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3:Full title of the trial`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.4.1:Sponsor's protocol code number`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.1:Name of Sponsor`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.3.4:Country`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.1:Name of organisation providing support`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.2:Country`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.1:Name of organisation`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.2:Functional name of contact point`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.1:Street Address`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.2:Town/ city`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.3:Post code`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.4:Country`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.4:Telephone number`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.5:Fax number`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.6:E-mail`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.1.2 and D.1.3:IMP Role`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5.1:Orphan drug designation number`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.1:Product name`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.2:Product code`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4:Pharmaceutical form`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4.1:Specific paediatric formulation`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.7:Routes of administration for this IMP`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.8:INN - Proposed INN`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.2:Current sponsor code`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.3:Other descriptive name`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.4:EV Substance Code`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.1:Concentration unit`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.2:Concentration type`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.3:Concentration number`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.1:Active substance of chemical origin`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.8:Extractive medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.9:Recombinant medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.11:Herbal medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.13:Another type of medicinal product`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.4:Route of administration of the placebo`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1:Medical condition(s) being investigated`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.2:Therapeutic area`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Version`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Level`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Classification code`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Term`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:System Organ Class`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.3:Condition being studied is a rare disease`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.1:Main objective of the trial`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.2:Secondary objectives of the trial`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.3:Trial contains a sub-study`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.3:Principal inclusion criteria`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.4:Principal exclusion criteria`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1:Primary end point(s)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2:Secondary end point(s)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.1:Diagnosis`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.2:Prophylaxis`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.3:Therapy`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.4:Safety`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.5:Efficacy`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.6:Pharmacokinetic`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.7:Pharmacodynamic`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.8:Bioequivalence`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.9:Dose response`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.10:Pharmacogenetic`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.11:Pharmacogenomic`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.12:Pharmacoeconomic`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.13:Others`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.1:First administration to humans`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.2:Bioequivalence study`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3:Other`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3.1:Other trial type description`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1:Controlled`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.1:Randomised`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.2:Open`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.3:Single blind`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.4:Double blind`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.5:Parallel group`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.6:Cross over`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.7:Other`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.1:Other medicinal product(s)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.2:Placebo`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.3:Other`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5:The trial involves multiple Member States`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.7:Trial has a data monitoring committee`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned years`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned months`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned days`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1:Trial has subjects under 18`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.1:In Utero`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.5:Children (2-11years)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2:Adults (18-64 years)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3:Elderly (>=65 years)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.1:Female`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.2:Male`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.1:Healthy volunteers`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.2:Patients`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3:Specific vulnerable populations`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.3:Pregnant women`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.4:Nursing women`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.5:Emergency situation`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.7:Others`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.1:In the member state`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.1:In the EEA`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.2:In the whole clinical trial`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Competent Authority Decision`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Competent Authority Decision`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Ethics Committee Opinion`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`P.:End of Trial Status`
      $`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.1:Member State Concerned`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.2:EudraCT number`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3:Full title of the trial`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.4.1:Sponsor's protocol code number`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.1:Name of Sponsor`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.3.4:Country`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.3.1 and B.3.2:Status of the sponsor`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.1:Name of organisation providing support`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.2:Country`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.1:Name of organisation`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.2:Functional name of contact point`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.1:Street Address`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.2:Town/ city`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.3:Post code`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.4:Country`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.4:Telephone number`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.5:Fax number`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.6:E-mail`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.1.2 and D.1.3:IMP Role`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5.1:Orphan drug designation number`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.1:Product name`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.2:Product code`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4:Pharmaceutical form`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4.1:Specific paediatric formulation`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.7:Routes of administration for this IMP`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.8:INN - Proposed INN`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.2:Current sponsor code`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.3:Other descriptive name`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.4:EV Substance Code`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.1:Concentration unit`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.2:Concentration type`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.3:Concentration number`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.1:Active substance of chemical origin`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.2:Gene therapy medical product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.3:Tissue Engineered Product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.7:Plasma derived medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.8:Extractive medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.9:Recombinant medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.11:Herbal medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.12:Homeopathic medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.13:Another type of medicinal product`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.1:Is a Placebo used in this Trial?`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.3:Pharmaceutical form of the placebo`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.4:Route of administration of the placebo`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1:Medical condition(s) being investigated`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.1:Medical condition in easily understood language`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.2:Therapeutic area`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Version`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Level`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Classification code`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Term`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:System Organ Class`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.3:Condition being studied is a rare disease`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.1:Main objective of the trial`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.2:Secondary objectives of the trial`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.3:Trial contains a sub-study`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.3:Principal inclusion criteria`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.4:Principal exclusion criteria`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1:Primary end point(s)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2:Secondary end point(s)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.1:Diagnosis`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.2:Prophylaxis`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.3:Therapy`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.4:Safety`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.5:Efficacy`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.6:Pharmacokinetic`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.7:Pharmacodynamic`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.8:Bioequivalence`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.9:Dose response`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.10:Pharmacogenetic`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.11:Pharmacogenomic`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.12:Pharmacoeconomic`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.13:Others`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1:Human pharmacology (Phase I)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.1:First administration to humans`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.2:Bioequivalence study`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3:Other`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3.1:Other trial type description`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.4:Therapeutic use (Phase IV)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1:Controlled`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.1:Randomised`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.2:Open`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.3:Single blind`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.4:Double blind`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.5:Parallel group`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.6:Cross over`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.7:Other`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.1:Other medicinal product(s)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.2:Placebo`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.3:Other`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.4:Number of treatment arms in the trial`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.3:The trial involves single site in the Member State concerned`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5:The trial involves multiple Member States`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.7:Trial has a data monitoring committee`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned years`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned months`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned days`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial years`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial months`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial days`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1:Trial has subjects under 18`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.1:In Utero`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.3:Newborns (0-27 days)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.5:Children (2-11years)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.6:Adolescents (12-17 years)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2:Adults (18-64 years)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2.1:Number of subjects for this age range:`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3:Elderly (>=65 years)`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3.1:Number of subjects for this age range:`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.1:Female`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.2:Male`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.1:Healthy volunteers`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.2:Patients`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3:Specific vulnerable populations`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.3:Pregnant women`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.4:Nursing women`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.5:Emergency situation`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.7:Others`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.1:In the member state`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.1:In the EEA`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.2:In the whole clinical trial`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$...
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$...[[1]]
      [1] "None"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Competent Authority Decision`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Competent Authority Decision`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion of the trial application`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Ethics Committee Opinion`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`P.:End of Trial Status`
      $`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      $`P. END OF TRIAL`
      $`P. END OF TRIAL`$`A.1:Member State Concerned`
      $`P. END OF TRIAL`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      $`P. END OF TRIAL`$`A.2:EudraCT number`
      $`P. END OF TRIAL`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      $`P. END OF TRIAL`$`A.3:Full title of the trial`
      $`P. END OF TRIAL`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      $`P. END OF TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      $`P. END OF TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      $`P. END OF TRIAL`$`A.4.1:Sponsor's protocol code number`
      $`P. END OF TRIAL`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      $`P. END OF TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      $`P. END OF TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      $`P. END OF TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`
      $`P. END OF TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      $`P. END OF TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      $`P. END OF TRIAL`$`B.1.1:Name of Sponsor`
      $`P. END OF TRIAL`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`P. END OF TRIAL`$`B.1.3.4:Country`
      $`P. END OF TRIAL`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      $`P. END OF TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`
      $`P. END OF TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      $`P. END OF TRIAL`$`B.4.1:Name of organisation providing support`
      $`P. END OF TRIAL`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      $`P. END OF TRIAL`$`B.4.2:Country`
      $`P. END OF TRIAL`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      $`P. END OF TRIAL`$`B.5.1:Name of organisation`
      $`P. END OF TRIAL`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      $`P. END OF TRIAL`$`B.5.2:Functional name of contact point`
      $`P. END OF TRIAL`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      $`P. END OF TRIAL`$`B.5.3.1:Street Address`
      $`P. END OF TRIAL`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      $`P. END OF TRIAL`$`B.5.3.2:Town/ city`
      $`P. END OF TRIAL`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      $`P. END OF TRIAL`$`B.5.3.3:Post code`
      $`P. END OF TRIAL`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      $`P. END OF TRIAL`$`B.5.3.4:Country`
      $`P. END OF TRIAL`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      $`P. END OF TRIAL`$`B.5.4:Telephone number`
      $`P. END OF TRIAL`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      $`P. END OF TRIAL`$`B.5.5:Fax number`
      $`P. END OF TRIAL`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      $`P. END OF TRIAL`$`B.5.6:E-mail`
      $`P. END OF TRIAL`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      $`P. END OF TRIAL`$`D.1.2 and D.1.3:IMP Role`
      $`P. END OF TRIAL`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      $`P. END OF TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      $`P. END OF TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      $`P. END OF TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.2.5.1:Orphan drug designation number`
      $`P. END OF TRIAL`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      $`P. END OF TRIAL`$`D.3.1:Product name`
      $`P. END OF TRIAL`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      $`P. END OF TRIAL`$`D.3.2:Product code`
      $`P. END OF TRIAL`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      $`P. END OF TRIAL`$`D.3.4:Pharmaceutical form`
      $`P. END OF TRIAL`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`P. END OF TRIAL`$`D.3.4.1:Specific paediatric formulation`
      $`P. END OF TRIAL`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.7:Routes of administration for this IMP`
      $`P. END OF TRIAL`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      $`P. END OF TRIAL`$`D.3.8:INN - Proposed INN`
      $`P. END OF TRIAL`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      $`P. END OF TRIAL`$`D.3.9.2:Current sponsor code`
      $`P. END OF TRIAL`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      $`P. END OF TRIAL`$`D.3.9.3:Other descriptive name`
      $`P. END OF TRIAL`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      $`P. END OF TRIAL`$`D.3.9.4:EV Substance Code`
      $`P. END OF TRIAL`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      $`P. END OF TRIAL`$`D.3.10.1:Concentration unit`
      $`P. END OF TRIAL`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      $`P. END OF TRIAL`$`D.3.10.2:Concentration type`
      $`P. END OF TRIAL`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      $`P. END OF TRIAL`$`D.3.10.3:Concentration number`
      $`P. END OF TRIAL`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      $`P. END OF TRIAL`$`D.3.11.1:Active substance of chemical origin`
      $`P. END OF TRIAL`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      $`P. END OF TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      $`P. END OF TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      $`P. END OF TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.3.2:Gene therapy medical product`
      $`P. END OF TRIAL`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.3.3:Tissue Engineered Product`
      $`P. END OF TRIAL`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      $`P. END OF TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      $`P. END OF TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      $`P. END OF TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`
      $`P. END OF TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      $`P. END OF TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.7:Plasma derived medicinal product`
      $`P. END OF TRIAL`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.8:Extractive medicinal product`
      $`P. END OF TRIAL`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.9:Recombinant medicinal product`
      $`P. END OF TRIAL`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      $`P. END OF TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.11:Herbal medicinal product`
      $`P. END OF TRIAL`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.12:Homeopathic medicinal product`
      $`P. END OF TRIAL`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.3.11.13:Another type of medicinal product`
      $`P. END OF TRIAL`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`D.8.1:Is a Placebo used in this Trial?`
      $`P. END OF TRIAL`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`D.8.3:Pharmaceutical form of the placebo`
      $`P. END OF TRIAL`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      $`P. END OF TRIAL`$`D.8.4:Route of administration of the placebo`
      $`P. END OF TRIAL`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      $`P. END OF TRIAL`$`E.1.1:Medical condition(s) being investigated`
      $`P. END OF TRIAL`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`P. END OF TRIAL`$`E.1.1.1:Medical condition in easily understood language`
      $`P. END OF TRIAL`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      $`P. END OF TRIAL`$`E.1.1.2:Therapeutic area`
      $`P. END OF TRIAL`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      $`P. END OF TRIAL`$`E.1.2:Version`
      $`P. END OF TRIAL`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      $`P. END OF TRIAL`$`E.1.2:Level`
      $`P. END OF TRIAL`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      $`P. END OF TRIAL`$`E.1.2:Classification code`
      $`P. END OF TRIAL`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      $`P. END OF TRIAL`$`E.1.2:Term`
      $`P. END OF TRIAL`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      $`P. END OF TRIAL`$`E.1.2:System Organ Class`
      $`P. END OF TRIAL`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      $`P. END OF TRIAL`$`E.1.3:Condition being studied is a rare disease`
      $`P. END OF TRIAL`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.2.1:Main objective of the trial`
      $`P. END OF TRIAL`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      $`P. END OF TRIAL`$`E.2.2:Secondary objectives of the trial`
      $`P. END OF TRIAL`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      $`P. END OF TRIAL`$`E.2.3:Trial contains a sub-study`
      $`P. END OF TRIAL`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.3:Principal inclusion criteria`
      $`P. END OF TRIAL`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      $`P. END OF TRIAL`$`E.4:Principal exclusion criteria`
      $`P. END OF TRIAL`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      $`P. END OF TRIAL`$`E.5.1:Primary end point(s)`
      $`P. END OF TRIAL`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      $`P. END OF TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      $`P. END OF TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      $`P. END OF TRIAL`$`E.5.2:Secondary end point(s)`
      $`P. END OF TRIAL`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      $`P. END OF TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      $`P. END OF TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      $`P. END OF TRIAL`$`E.6.1:Diagnosis`
      $`P. END OF TRIAL`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.6.2:Prophylaxis`
      $`P. END OF TRIAL`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.6.3:Therapy`
      $`P. END OF TRIAL`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.4:Safety`
      $`P. END OF TRIAL`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.5:Efficacy`
      $`P. END OF TRIAL`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.6:Pharmacokinetic`
      $`P. END OF TRIAL`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.7:Pharmacodynamic`
      $`P. END OF TRIAL`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.8:Bioequivalence`
      $`P. END OF TRIAL`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.6.9:Dose response`
      $`P. END OF TRIAL`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.10:Pharmacogenetic`
      $`P. END OF TRIAL`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.11:Pharmacogenomic`
      $`P. END OF TRIAL`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.12:Pharmacoeconomic`
      $`P. END OF TRIAL`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.6.13:Others`
      $`P. END OF TRIAL`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.7.1:Human pharmacology (Phase I)`
      $`P. END OF TRIAL`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.7.1.1:First administration to humans`
      $`P. END OF TRIAL`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.7.1.2:Bioequivalence study`
      $`P. END OF TRIAL`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.7.1.3:Other`
      $`P. END OF TRIAL`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.7.1.3.1:Other trial type description`
      $`P. END OF TRIAL`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      $`P. END OF TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`
      $`P. END OF TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`
      $`P. END OF TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.7.4:Therapeutic use (Phase IV)`
      $`P. END OF TRIAL`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.1:Controlled`
      $`P. END OF TRIAL`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.1.1:Randomised`
      $`P. END OF TRIAL`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.1.2:Open`
      $`P. END OF TRIAL`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.1.3:Single blind`
      $`P. END OF TRIAL`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.1.4:Double blind`
      $`P. END OF TRIAL`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.1.5:Parallel group`
      $`P. END OF TRIAL`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.1.6:Cross over`
      $`P. END OF TRIAL`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.1.7:Other`
      $`P. END OF TRIAL`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.2.1:Other medicinal product(s)`
      $`P. END OF TRIAL`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.2.2:Placebo`
      $`P. END OF TRIAL`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.2.3:Other`
      $`P. END OF TRIAL`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.2.4:Number of treatment arms in the trial`
      $`P. END OF TRIAL`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      $`P. END OF TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`
      $`P. END OF TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      $`P. END OF TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      $`P. END OF TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      $`P. END OF TRIAL`$`E.8.5:The trial involves multiple Member States`
      $`P. END OF TRIAL`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`
      $`P. END OF TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      $`P. END OF TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      $`P. END OF TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      $`P. END OF TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      $`P. END OF TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      $`P. END OF TRIAL`$`E.8.7:Trial has a data monitoring committee`
      $`P. END OF TRIAL`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      $`P. END OF TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      $`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned years`
      $`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      $`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned months`
      $`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      $`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned days`
      $`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      $`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial years`
      $`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      $`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial months`
      $`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      $`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial days`
      $`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      $`P. END OF TRIAL`$`F.1.1:Trial has subjects under 18`
      $`P. END OF TRIAL`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.1.1:In Utero`
      $`P. END OF TRIAL`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      $`P. END OF TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.1.3:Newborns (0-27 days)`
      $`P. END OF TRIAL`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      $`P. END OF TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.1.5:Children (2-11years)`
      $`P. END OF TRIAL`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.1.6:Adolescents (12-17 years)`
      $`P. END OF TRIAL`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.1.2:Adults (18-64 years)`
      $`P. END OF TRIAL`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.1.2.1:Number of subjects for this age range:`
      $`P. END OF TRIAL`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      $`P. END OF TRIAL`$`F.1.3:Elderly (>=65 years)`
      $`P. END OF TRIAL`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.1.3.1:Number of subjects for this age range:`
      $`P. END OF TRIAL`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      $`P. END OF TRIAL`$`F.2.1:Female`
      $`P. END OF TRIAL`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.2.2:Male`
      $`P. END OF TRIAL`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.3.1:Healthy volunteers`
      $`P. END OF TRIAL`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.3.2:Patients`
      $`P. END OF TRIAL`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.3.3:Specific vulnerable populations`
      $`P. END OF TRIAL`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`
      $`P. END OF TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`
      $`P. END OF TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      $`P. END OF TRIAL`$`F.3.3.3:Pregnant women`
      $`P. END OF TRIAL`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.3.3.4:Nursing women`
      $`P. END OF TRIAL`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.3.3.5:Emergency situation`
      $`P. END OF TRIAL`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`
      $`P. END OF TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.3.3.7:Others`
      $`P. END OF TRIAL`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      $`P. END OF TRIAL`$`F.4.1:In the member state`
      $`P. END OF TRIAL`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      $`P. END OF TRIAL`$`F.4.2.1:In the EEA`
      $`P. END OF TRIAL`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      $`P. END OF TRIAL`$`F.4.2.2:In the whole clinical trial`
      $`P. END OF TRIAL`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      $`P. END OF TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      $`P. END OF TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      $`P. END OF TRIAL`$`N.:Competent Authority Decision`
      $`P. END OF TRIAL`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      $`P. END OF TRIAL`$`N.:Date of Competent Authority Decision`
      $`P. END OF TRIAL`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      $`P. END OF TRIAL`$`N.:Ethics Committee Opinion of the trial application`
      $`P. END OF TRIAL`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      $`P. END OF TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      $`P. END OF TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      $`P. END OF TRIAL`$`N.:Date of Ethics Committee Opinion`
      $`P. END OF TRIAL`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      $`P. END OF TRIAL`$`P.:End of Trial Status`
      $`P. END OF TRIAL`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      

# Test search_studies

    Code
      search_studies("EFC14280")
    Output
      [[1]]
      [[1]]$`A. PROTOCOL INFORMATION`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.1:Member State Concerned`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.2:EudraCT number`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.3:Full title of the trial`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`A. PROTOCOL INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.1.1:Name of Sponsor`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.1.3.4:Country`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.4.1:Name of organisation providing support`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.4.2:Country`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.1:Name of organisation`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.2:Functional name of contact point`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.1:Street Address`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.2:Town/ city`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.3:Post code`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.4:Country`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.4:Telephone number`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.5:Fax number`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.6:E-mail`
      [[1]]$`A. PROTOCOL INFORMATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.1:Product name`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.2:Product code`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.4:Pharmaceutical form`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.8:INN - Proposed INN`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.9.2:Current sponsor code`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.9.3:Other descriptive name`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.9.4:EV Substance Code`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.10.1:Concentration unit`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.10.2:Concentration type`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.10.3:Concentration number`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`D.8.4:Route of administration of the placebo`
      [[1]]$`A. PROTOCOL INFORMATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.1.2:Therapeutic area`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Version`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Level`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Classification code`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Term`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:System Organ Class`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.2.1:Main objective of the trial`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.2.3:Trial contains a sub-study`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.3:Principal inclusion criteria`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.4:Principal exclusion criteria`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.1:Primary end point(s)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.2:Secondary end point(s)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.1:Diagnosis`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.2:Prophylaxis`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.3:Therapy`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.4:Safety`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.5:Efficacy`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.6:Pharmacokinetic`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.7:Pharmacodynamic`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.8:Bioequivalence`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.9:Dose response`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.10:Pharmacogenetic`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.11:Pharmacogenomic`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.12:Pharmacoeconomic`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.13:Others`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.1:First administration to humans`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.2:Bioequivalence study`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.3:Other`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.3.1:Other trial type description`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1:Controlled`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.1:Randomised`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.2:Open`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.3:Single blind`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.4:Double blind`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.5:Parallel group`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.6:Cross over`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.7:Other`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.2:Placebo`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.3:Other`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`A. PROTOCOL INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1:Trial has subjects under 18`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.1:In Utero`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.5:Children (2-11years)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.2:Adults (18-64 years)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.2.1:Female`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.2.2:Male`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.1:Healthy volunteers`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.2:Patients`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3:Specific vulnerable populations`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.3:Pregnant women`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.4:Nursing women`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.5:Emergency situation`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.7:Others`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.4.1:In the member state`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.4.2.1:In the EEA`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`A. PROTOCOL INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Competent Authority Decision`
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Date of Competent Authority Decision`
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`A. PROTOCOL INFORMATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`A. PROTOCOL INFORMATION`$`P.:End of Trial Status`
      [[1]]$`A. PROTOCOL INFORMATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`B. SPONSOR INFORMATION`
      [[1]]$`B. SPONSOR INFORMATION`$`A.1:Member State Concerned`
      [[1]]$`B. SPONSOR INFORMATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.2:EudraCT number`
      [[1]]$`B. SPONSOR INFORMATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.3:Full title of the trial`
      [[1]]$`B. SPONSOR INFORMATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`B. SPONSOR INFORMATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`B. SPONSOR INFORMATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`B. SPONSOR INFORMATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`B. SPONSOR INFORMATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`B. SPONSOR INFORMATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.1.1:Name of Sponsor`
      [[1]]$`B. SPONSOR INFORMATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.1.3.4:Country`
      [[1]]$`B. SPONSOR INFORMATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`B. SPONSOR INFORMATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.4.1:Name of organisation providing support`
      [[1]]$`B. SPONSOR INFORMATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.4.2:Country`
      [[1]]$`B. SPONSOR INFORMATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.1:Name of organisation`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.2:Functional name of contact point`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.1:Street Address`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.2:Town/ city`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.3:Post code`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.4:Country`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.4:Telephone number`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.5:Fax number`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.6:E-mail`
      [[1]]$`B. SPONSOR INFORMATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`B. SPONSOR INFORMATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`B. SPONSOR INFORMATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`B. SPONSOR INFORMATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`B. SPONSOR INFORMATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.1:Product name`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.2:Product code`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.4:Pharmaceutical form`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.8:INN - Proposed INN`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.9.2:Current sponsor code`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.9.3:Other descriptive name`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.9.4:EV Substance Code`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.10.1:Concentration unit`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.10.2:Concentration type`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.10.3:Concentration number`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`B. SPONSOR INFORMATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`B. SPONSOR INFORMATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`B. SPONSOR INFORMATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`D.8.4:Route of administration of the placebo`
      [[1]]$`B. SPONSOR INFORMATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.1.2:Therapeutic area`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Version`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Level`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Classification code`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Term`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:System Organ Class`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`B. SPONSOR INFORMATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.2.1:Main objective of the trial`
      [[1]]$`B. SPONSOR INFORMATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`B. SPONSOR INFORMATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.2.3:Trial contains a sub-study`
      [[1]]$`B. SPONSOR INFORMATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.3:Principal inclusion criteria`
      [[1]]$`B. SPONSOR INFORMATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.4:Principal exclusion criteria`
      [[1]]$`B. SPONSOR INFORMATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.1:Primary end point(s)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.2:Secondary end point(s)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`B. SPONSOR INFORMATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.1:Diagnosis`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.2:Prophylaxis`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.3:Therapy`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.4:Safety`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.5:Efficacy`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.6:Pharmacokinetic`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.7:Pharmacodynamic`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.8:Bioequivalence`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.9:Dose response`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.10:Pharmacogenetic`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.11:Pharmacogenomic`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.12:Pharmacoeconomic`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.13:Others`
      [[1]]$`B. SPONSOR INFORMATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.1:First administration to humans`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.2:Bioequivalence study`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.3:Other`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.3.1:Other trial type description`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1:Controlled`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.1:Randomised`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.2:Open`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.3:Single blind`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.4:Double blind`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.5:Parallel group`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.6:Cross over`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.7:Other`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.2:Placebo`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.3:Other`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`B. SPONSOR INFORMATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1:Trial has subjects under 18`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.1:In Utero`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.5:Children (2-11years)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.2:Adults (18-64 years)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`B. SPONSOR INFORMATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.2.1:Female`
      [[1]]$`B. SPONSOR INFORMATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.2.2:Male`
      [[1]]$`B. SPONSOR INFORMATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.1:Healthy volunteers`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.2:Patients`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3:Specific vulnerable populations`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.3:Pregnant women`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.4:Nursing women`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.5:Emergency situation`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.7:Others`
      [[1]]$`B. SPONSOR INFORMATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.4.1:In the member state`
      [[1]]$`B. SPONSOR INFORMATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.4.2.1:In the EEA`
      [[1]]$`B. SPONSOR INFORMATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`B. SPONSOR INFORMATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`B. SPONSOR INFORMATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Competent Authority Decision`
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Date of Competent Authority Decision`
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`B. SPONSOR INFORMATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`B. SPONSOR INFORMATION`$`P.:End of Trial Status`
      [[1]]$`B. SPONSOR INFORMATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.1:Member State Concerned`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.2:EudraCT number`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.3:Full title of the trial`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.1.1:Name of Sponsor`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.1.3.4:Country`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.4.1:Name of organisation providing support`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.4.2:Country`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.1:Name of organisation`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.2:Functional name of contact point`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.1:Street Address`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.2:Town/ city`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.3:Post code`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.4:Country`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.4:Telephone number`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.5:Fax number`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.6:E-mail`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.1:Product name`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.2:Product code`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.4:Pharmaceutical form`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.8:INN - Proposed INN`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.9.2:Current sponsor code`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.9.3:Other descriptive name`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.9.4:EV Substance Code`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.10.1:Concentration unit`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.10.2:Concentration type`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.10.3:Concentration number`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.8.4:Route of administration of the placebo`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.1.2:Therapeutic area`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Version`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Level`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Classification code`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Term`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:System Organ Class`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.2.1:Main objective of the trial`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.2.3:Trial contains a sub-study`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.3:Principal inclusion criteria`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.4:Principal exclusion criteria`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.1:Primary end point(s)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.2:Secondary end point(s)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.1:Diagnosis`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.2:Prophylaxis`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.3:Therapy`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.4:Safety`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.5:Efficacy`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.6:Pharmacokinetic`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.7:Pharmacodynamic`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.8:Bioequivalence`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.9:Dose response`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.10:Pharmacogenetic`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.11:Pharmacogenomic`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.12:Pharmacoeconomic`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.13:Others`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.1:First administration to humans`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.2:Bioequivalence study`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.3:Other`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.3.1:Other trial type description`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1:Controlled`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.1:Randomised`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.2:Open`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.3:Single blind`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.4:Double blind`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.5:Parallel group`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.6:Cross over`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.7:Other`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.2:Placebo`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.3:Other`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1:Trial has subjects under 18`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.1:In Utero`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.5:Children (2-11years)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.2:Adults (18-64 years)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.2.1:Female`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.2.2:Male`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.1:Healthy volunteers`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.2:Patients`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3:Specific vulnerable populations`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.3:Pregnant women`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.4:Nursing women`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.5:Emergency situation`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.7:Others`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.4.1:In the member state`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.4.2.1:In the EEA`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Competent Authority Decision`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Date of Competent Authority Decision`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`C. APPLICANT IDENTIFICATION`$`P.:End of Trial Status`
      [[1]]$`C. APPLICANT IDENTIFICATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`D. IMP IDENTIFICATION`
      [[1]]$`D. IMP IDENTIFICATION`$`A.1:Member State Concerned`
      [[1]]$`D. IMP IDENTIFICATION`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.2:EudraCT number`
      [[1]]$`D. IMP IDENTIFICATION`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.3:Full title of the trial`
      [[1]]$`D. IMP IDENTIFICATION`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`D. IMP IDENTIFICATION`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`D. IMP IDENTIFICATION`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`D. IMP IDENTIFICATION`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`D. IMP IDENTIFICATION`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`D. IMP IDENTIFICATION`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.1.1:Name of Sponsor`
      [[1]]$`D. IMP IDENTIFICATION`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.1.3.4:Country`
      [[1]]$`D. IMP IDENTIFICATION`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`D. IMP IDENTIFICATION`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.4.1:Name of organisation providing support`
      [[1]]$`D. IMP IDENTIFICATION`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.4.2:Country`
      [[1]]$`D. IMP IDENTIFICATION`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.1:Name of organisation`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.2:Functional name of contact point`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.1:Street Address`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.2:Town/ city`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.3:Post code`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.4:Country`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.4:Telephone number`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.5:Fax number`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.6:E-mail`
      [[1]]$`D. IMP IDENTIFICATION`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`D. IMP IDENTIFICATION`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`D. IMP IDENTIFICATION`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`D. IMP IDENTIFICATION`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`D. IMP IDENTIFICATION`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.1:Product name`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.2:Product code`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.4:Pharmaceutical form`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.8:INN - Proposed INN`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.9.2:Current sponsor code`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.9.3:Other descriptive name`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.9.4:EV Substance Code`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.10.1:Concentration unit`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.10.2:Concentration type`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.10.3:Concentration number`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`D. IMP IDENTIFICATION`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`D. IMP IDENTIFICATION`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`D. IMP IDENTIFICATION`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`D.8.4:Route of administration of the placebo`
      [[1]]$`D. IMP IDENTIFICATION`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.1.2:Therapeutic area`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Version`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Level`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Classification code`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Term`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:System Organ Class`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`D. IMP IDENTIFICATION`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.2.1:Main objective of the trial`
      [[1]]$`D. IMP IDENTIFICATION`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`D. IMP IDENTIFICATION`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.2.3:Trial contains a sub-study`
      [[1]]$`D. IMP IDENTIFICATION`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.3:Principal inclusion criteria`
      [[1]]$`D. IMP IDENTIFICATION`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.4:Principal exclusion criteria`
      [[1]]$`D. IMP IDENTIFICATION`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.1:Primary end point(s)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.2:Secondary end point(s)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`D. IMP IDENTIFICATION`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.1:Diagnosis`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.2:Prophylaxis`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.3:Therapy`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.4:Safety`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.5:Efficacy`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.6:Pharmacokinetic`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.7:Pharmacodynamic`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.8:Bioequivalence`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.9:Dose response`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.10:Pharmacogenetic`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.11:Pharmacogenomic`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.12:Pharmacoeconomic`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.13:Others`
      [[1]]$`D. IMP IDENTIFICATION`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.1:First administration to humans`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.2:Bioequivalence study`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.3:Other`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.3.1:Other trial type description`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1:Controlled`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.1:Randomised`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.2:Open`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.3:Single blind`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.4:Double blind`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.5:Parallel group`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.6:Cross over`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.7:Other`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.2:Placebo`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.3:Other`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`D. IMP IDENTIFICATION`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1:Trial has subjects under 18`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.1:In Utero`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.5:Children (2-11years)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.2:Adults (18-64 years)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`D. IMP IDENTIFICATION`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.2.1:Female`
      [[1]]$`D. IMP IDENTIFICATION`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.2.2:Male`
      [[1]]$`D. IMP IDENTIFICATION`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.1:Healthy volunteers`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.2:Patients`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3:Specific vulnerable populations`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.3:Pregnant women`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.4:Nursing women`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.5:Emergency situation`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.7:Others`
      [[1]]$`D. IMP IDENTIFICATION`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.4.1:In the member state`
      [[1]]$`D. IMP IDENTIFICATION`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.4.2.1:In the EEA`
      [[1]]$`D. IMP IDENTIFICATION`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`D. IMP IDENTIFICATION`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`D. IMP IDENTIFICATION`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Competent Authority Decision`
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Date of Competent Authority Decision`
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`D. IMP IDENTIFICATION`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`D. IMP IDENTIFICATION`$`P.:End of Trial Status`
      [[1]]$`D. IMP IDENTIFICATION`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.1:Member State Concerned`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.2:EudraCT number`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.3:Full title of the trial`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.1:Name of Sponsor`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.3.4:Country`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.1:Name of organisation providing support`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.2:Country`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.1:Name of organisation`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.2:Functional name of contact point`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.1:Street Address`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.2:Town/ city`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.3:Post code`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.4:Country`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.4:Telephone number`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.5:Fax number`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.6:E-mail`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.1:Product name`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.2:Product code`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4:Pharmaceutical form`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.8:INN - Proposed INN`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.2:Current sponsor code`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.3:Other descriptive name`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.4:EV Substance Code`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.1:Concentration unit`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.2:Concentration type`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.3:Concentration number`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.4:Route of administration of the placebo`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.2:Therapeutic area`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Version`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Level`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Classification code`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Term`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:System Organ Class`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.1:Main objective of the trial`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.3:Trial contains a sub-study`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.3:Principal inclusion criteria`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.4:Principal exclusion criteria`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1:Primary end point(s)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2:Secondary end point(s)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.1:Diagnosis`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.2:Prophylaxis`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.3:Therapy`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.4:Safety`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.5:Efficacy`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.6:Pharmacokinetic`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.7:Pharmacodynamic`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.8:Bioequivalence`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.9:Dose response`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.10:Pharmacogenetic`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.11:Pharmacogenomic`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.12:Pharmacoeconomic`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.13:Others`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.1:First administration to humans`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.2:Bioequivalence study`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3:Other`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3.1:Other trial type description`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1:Controlled`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.1:Randomised`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.2:Open`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.3:Single blind`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.4:Double blind`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.5:Parallel group`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.6:Cross over`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.7:Other`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.2:Placebo`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.3:Other`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1:Trial has subjects under 18`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.1:In Utero`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.5:Children (2-11years)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2:Adults (18-64 years)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.1:Female`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.2:Male`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.1:Healthy volunteers`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.2:Patients`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3:Specific vulnerable populations`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.3:Pregnant women`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.4:Nursing women`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.5:Emergency situation`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.7:Others`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.1:In the member state`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.1:In the EEA`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Competent Authority Decision`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Competent Authority Decision`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`P.:End of Trial Status`
      [[1]]$`E. GENERAL INFORMATION ON THE TRIAL`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.1:Member State Concerned`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.2:EudraCT number`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.3:Full title of the trial`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.1.1:Name of Sponsor`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.1.3.4:Country`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.4.1:Name of organisation providing support`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.4.2:Country`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.1:Name of organisation`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.2:Functional name of contact point`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.1:Street Address`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.2:Town/ city`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.3:Post code`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.4:Country`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.4:Telephone number`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.5:Fax number`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.6:E-mail`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.1:Product name`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.2:Product code`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4:Pharmaceutical form`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.8:INN - Proposed INN`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.2:Current sponsor code`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.3:Other descriptive name`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.4:EV Substance Code`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.1:Concentration unit`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.2:Concentration type`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.3:Concentration number`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.8.4:Route of administration of the placebo`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.2:Therapeutic area`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Version`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Level`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Classification code`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Term`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:System Organ Class`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.2.1:Main objective of the trial`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.2.3:Trial contains a sub-study`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.3:Principal inclusion criteria`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.4:Principal exclusion criteria`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1:Primary end point(s)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2:Secondary end point(s)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.1:Diagnosis`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.2:Prophylaxis`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.3:Therapy`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.4:Safety`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.5:Efficacy`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.6:Pharmacokinetic`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.7:Pharmacodynamic`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.8:Bioequivalence`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.9:Dose response`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.10:Pharmacogenetic`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.11:Pharmacogenomic`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.12:Pharmacoeconomic`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.13:Others`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.1:First administration to humans`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.2:Bioequivalence study`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3:Other`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3.1:Other trial type description`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1:Controlled`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.1:Randomised`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.2:Open`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.3:Single blind`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.4:Double blind`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.5:Parallel group`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.6:Cross over`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.7:Other`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.2:Placebo`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.3:Other`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1:Trial has subjects under 18`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.1:In Utero`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.5:Children (2-11years)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2:Adults (18-64 years)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.2.1:Female`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.2.2:Male`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.1:Healthy volunteers`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.2:Patients`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3:Specific vulnerable populations`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.3:Pregnant women`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.4:Nursing women`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.5:Emergency situation`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.7:Others`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.4.1:In the member state`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.1:In the EEA`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Competent Authority Decision`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Competent Authority Decision`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`P.:End of Trial Status`
      [[1]]$`F. POPULATION OF TRIAL SUBJECTS`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.1:Member State Concerned`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.2:EudraCT number`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3:Full title of the trial`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.1:Name of Sponsor`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.3.4:Country`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.1:Name of organisation providing support`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.2:Country`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.1:Name of organisation`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.2:Functional name of contact point`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.1:Street Address`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.2:Town/ city`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.3:Post code`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.4:Country`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.4:Telephone number`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.5:Fax number`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.6:E-mail`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.1:Product name`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.2:Product code`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4:Pharmaceutical form`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.8:INN - Proposed INN`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.2:Current sponsor code`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.3:Other descriptive name`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.4:EV Substance Code`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.1:Concentration unit`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.2:Concentration type`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.3:Concentration number`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.4:Route of administration of the placebo`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.2:Therapeutic area`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Version`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Level`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Classification code`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Term`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:System Organ Class`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.1:Main objective of the trial`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.3:Trial contains a sub-study`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.3:Principal inclusion criteria`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.4:Principal exclusion criteria`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1:Primary end point(s)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2:Secondary end point(s)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.1:Diagnosis`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.2:Prophylaxis`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.3:Therapy`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.4:Safety`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.5:Efficacy`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.6:Pharmacokinetic`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.7:Pharmacodynamic`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.8:Bioequivalence`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.9:Dose response`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.10:Pharmacogenetic`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.11:Pharmacogenomic`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.12:Pharmacoeconomic`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.13:Others`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.1:First administration to humans`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.2:Bioequivalence study`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3:Other`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3.1:Other trial type description`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1:Controlled`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.1:Randomised`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.2:Open`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.3:Single blind`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.4:Double blind`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.5:Parallel group`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.6:Cross over`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.7:Other`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.2:Placebo`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.3:Other`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1:Trial has subjects under 18`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.1:In Utero`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.5:Children (2-11years)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2:Adults (18-64 years)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.1:Female`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.2:Male`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.1:Healthy volunteers`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.2:Patients`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3:Specific vulnerable populations`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.3:Pregnant women`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.4:Nursing women`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.5:Emergency situation`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.7:Others`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.1:In the member state`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.1:In the EEA`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Competent Authority Decision`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Competent Authority Decision`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`P.:End of Trial Status`
      [[1]]$`G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.1:Member State Concerned`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.2:EudraCT number`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3:Full title of the trial`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.1:Name of Sponsor`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.3.4:Country`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.1:Name of organisation providing support`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.2:Country`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.1:Name of organisation`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.2:Functional name of contact point`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.1:Street Address`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.2:Town/ city`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.3:Post code`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.4:Country`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.4:Telephone number`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.5:Fax number`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.6:E-mail`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.1:Product name`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.2:Product code`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4:Pharmaceutical form`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.8:INN - Proposed INN`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.2:Current sponsor code`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.3:Other descriptive name`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.4:EV Substance Code`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.1:Concentration unit`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.2:Concentration type`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.3:Concentration number`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.4:Route of administration of the placebo`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.2:Therapeutic area`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Version`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Level`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Classification code`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Term`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:System Organ Class`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.1:Main objective of the trial`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.3:Trial contains a sub-study`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.3:Principal inclusion criteria`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.4:Principal exclusion criteria`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1:Primary end point(s)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2:Secondary end point(s)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.1:Diagnosis`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.2:Prophylaxis`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.3:Therapy`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.4:Safety`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.5:Efficacy`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.6:Pharmacokinetic`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.7:Pharmacodynamic`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.8:Bioequivalence`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.9:Dose response`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.10:Pharmacogenetic`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.11:Pharmacogenomic`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.12:Pharmacoeconomic`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.13:Others`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.1:First administration to humans`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.2:Bioequivalence study`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3:Other`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3.1:Other trial type description`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1:Controlled`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.1:Randomised`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.2:Open`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.3:Single blind`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.4:Double blind`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.5:Parallel group`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.6:Cross over`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.7:Other`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.2:Placebo`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.3:Other`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1:Trial has subjects under 18`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.1:In Utero`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.5:Children (2-11years)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2:Adults (18-64 years)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.1:Female`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.2:Male`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.1:Healthy volunteers`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.2:Patients`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3:Specific vulnerable populations`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.3:Pregnant women`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.4:Nursing women`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.5:Emergency situation`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.7:Others`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.1:In the member state`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.1:In the EEA`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$...
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$...[[1]]
      [1] "None"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Competent Authority Decision`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Competent Authority Decision`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`P.:End of Trial Status`
      [[1]]$`N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      [[1]]$`P. END OF TRIAL`
      [[1]]$`P. END OF TRIAL`$`A.1:Member State Concerned`
      [[1]]$`P. END OF TRIAL`$`A.1:Member State Concerned`[[1]]
      [1] "Sweden - MPA"
      
      
      [[1]]$`P. END OF TRIAL`$`A.2:EudraCT number`
      [[1]]$`P. END OF TRIAL`$`A.2:EudraCT number`[[1]]
      [1] "2015-001314-10"
      
      
      [[1]]$`P. END OF TRIAL`$`A.3:Full title of the trial`
      [[1]]$`P. END OF TRIAL`$`A.3:Full title of the trial`[[1]]
      [1] "A Randomized, Double-blind, 52-week, Placebo Controlled Efficacy and Safety Study of Dupilumab, in Patients with Bilateral Nasal Polyposis on a Background Therapy with Intranasal Corticosteroids"
      
      
      [[1]]$`P. END OF TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`
      [[1]]$`P. END OF TRIAL`$`A.3.1:Title of the trial for lay people, in easily understood, i.e. non-technical, language`[[1]]
      [1] "Controlled Clinical Study of Dupilumab in Patients with Nasal Polyps"
      
      
      [[1]]$`P. END OF TRIAL`$`A.4.1:Sponsor's protocol code number`
      [[1]]$`P. END OF TRIAL`$`A.4.1:Sponsor's protocol code number`[[1]]
      [1] "EFC14280"
      
      
      [[1]]$`P. END OF TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`
      [[1]]$`P. END OF TRIAL`$`A.5.3:WHO Universal Trial Reference Number (UTRN)`[[1]]
      [1] "U1111-1170-7180"
      
      
      [[1]]$`P. END OF TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`
      [[1]]$`P. END OF TRIAL`$`A.7:Trial is part of a Paediatric Investigation Plan`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`
      [[1]]$`P. END OF TRIAL`$`A.8:EMA Decision number of Paediatric Investigation Plan`[[1]]
      [1] ""
      
      
      [[1]]$`P. END OF TRIAL`$`B.1.1:Name of Sponsor`
      [[1]]$`P. END OF TRIAL`$`B.1.1:Name of Sponsor`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`P. END OF TRIAL`$`B.1.3.4:Country`
      [[1]]$`P. END OF TRIAL`$`B.1.3.4:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`P. END OF TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`
      [[1]]$`P. END OF TRIAL`$`B.3.1 and B.3.2:Status of the sponsor`[[1]]
      [1] "Commercial"
      
      
      [[1]]$`P. END OF TRIAL`$`B.4.1:Name of organisation providing support`
      [[1]]$`P. END OF TRIAL`$`B.4.1:Name of organisation providing support`[[1]]
      [1] "SANOFI-AVENTIS RECHERCHE ET DEVELOPPEMENT"
      
      
      [[1]]$`P. END OF TRIAL`$`B.4.2:Country`
      [[1]]$`P. END OF TRIAL`$`B.4.2:Country`[[1]]
      [1] "France"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.1:Name of organisation`
      [[1]]$`P. END OF TRIAL`$`B.5.1:Name of organisation`[[1]]
      [1] "Sanofi AB"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.2:Functional name of contact point`
      [[1]]$`P. END OF TRIAL`$`B.5.2:Functional name of contact point`[[1]]
      [1] "Country Team Manager Sweden"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.3.1:Street Address`
      [[1]]$`P. END OF TRIAL`$`B.5.3.1:Street Address`[[1]]
      [1] "Box 30052"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.3.2:Town/ city`
      [[1]]$`P. END OF TRIAL`$`B.5.3.2:Town/ city`[[1]]
      [1] "Stockholm"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.3.3:Post code`
      [[1]]$`P. END OF TRIAL`$`B.5.3.3:Post code`[[1]]
      [1] "104 25"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.3.4:Country`
      [[1]]$`P. END OF TRIAL`$`B.5.3.4:Country`[[1]]
      [1] "Sweden"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.4:Telephone number`
      [[1]]$`P. END OF TRIAL`$`B.5.4:Telephone number`[[1]]
      [1] "+ 46 8 634 5000"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.5:Fax number`
      [[1]]$`P. END OF TRIAL`$`B.5.5:Fax number`[[1]]
      [1] "+ 46 8 634 5001"
      
      
      [[1]]$`P. END OF TRIAL`$`B.5.6:E-mail`
      [[1]]$`P. END OF TRIAL`$`B.5.6:E-mail`[[1]]
      [1] "clinicaltrials.sweden@sanofi.com"
      
      
      [[1]]$`P. END OF TRIAL`$`D.1.2 and D.1.3:IMP Role`
      [[1]]$`P. END OF TRIAL`$`D.1.2 and D.1.3:IMP Role`[[1]]
      [1] "Test"
      
      
      [[1]]$`P. END OF TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`
      [[1]]$`P. END OF TRIAL`$`D.2.1:IMP to be used in the trial has a marketing authorisation`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`
      [[1]]$`P. END OF TRIAL`$`D.2.5:The IMP has been designated in this indication as an orphan drug in the Community`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.2.5.1:Orphan drug designation number`
      [[1]]$`P. END OF TRIAL`$`D.2.5.1:Orphan drug designation number`[[1]]
      [1] ""
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.1:Product name`
      [[1]]$`P. END OF TRIAL`$`D.3.1:Product name`[[1]]
      [1] "dupilumab"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.2:Product code`
      [[1]]$`P. END OF TRIAL`$`D.3.2:Product code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.4:Pharmaceutical form`
      [[1]]$`P. END OF TRIAL`$`D.3.4:Pharmaceutical form`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.4.1:Specific paediatric formulation`
      [[1]]$`P. END OF TRIAL`$`D.3.4.1:Specific paediatric formulation`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.7:Routes of administration for this IMP`
      [[1]]$`P. END OF TRIAL`$`D.3.7:Routes of administration for this IMP`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.8:INN - Proposed INN`
      [[1]]$`P. END OF TRIAL`$`D.3.8:INN - Proposed INN`[[1]]
      [1] "Dupilumab"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.9.2:Current sponsor code`
      [[1]]$`P. END OF TRIAL`$`D.3.9.2:Current sponsor code`[[1]]
      [1] "SAR231893"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.9.3:Other descriptive name`
      [[1]]$`P. END OF TRIAL`$`D.3.9.3:Other descriptive name`[[1]]
      [1] "REGN668"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.9.4:EV Substance Code`
      [[1]]$`P. END OF TRIAL`$`D.3.9.4:EV Substance Code`[[1]]
      [1] "SUB88511"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.10.1:Concentration unit`
      [[1]]$`P. END OF TRIAL`$`D.3.10.1:Concentration unit`[[1]]
      [1] "mg/ml milligram(s)/millilitre"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.10.2:Concentration type`
      [[1]]$`P. END OF TRIAL`$`D.3.10.2:Concentration type`[[1]]
      [1] "equal"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.10.3:Concentration number`
      [[1]]$`P. END OF TRIAL`$`D.3.10.3:Concentration number`[[1]]
      [1] "150"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.1:Active substance of chemical origin`
      [[1]]$`P. END OF TRIAL`$`D.3.11.1:Active substance of chemical origin`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`
      [[1]]$`P. END OF TRIAL`$`D.3.11.2:Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`
      [[1]]$`P. END OF TRIAL`$`D.3.11.3:Advanced Therapy IMP (ATIMP)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.1:Somatic cell therapy medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.2:Gene therapy medical product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.2:Gene therapy medical product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.3:Tissue Engineered Product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.3:Tissue Engineered Product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.4:Combination ATIMP (i.e. one involving a medical device)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.3.5:Committee on Advanced therapies (CAT) has issued a classification for this product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`
      [[1]]$`P. END OF TRIAL`$`D.3.11.4:Combination product that includes a device, but does not involve an Advanced Therapy`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.5:Radiopharmaceutical medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`
      [[1]]$`P. END OF TRIAL`$`D.3.11.6:Immunological medicinal product (such as vaccine, allergen, immune serum)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.7:Plasma derived medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.7:Plasma derived medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.8:Extractive medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.8:Extractive medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.9:Recombinant medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.9:Recombinant medicinal product`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`
      [[1]]$`P. END OF TRIAL`$`D.3.11.10:Medicinal product containing genetically modified organisms`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.11:Herbal medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.11:Herbal medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.12:Homeopathic medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.12:Homeopathic medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.3.11.13:Another type of medicinal product`
      [[1]]$`P. END OF TRIAL`$`D.3.11.13:Another type of medicinal product`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`D.8.1:Is a Placebo used in this Trial?`
      [[1]]$`P. END OF TRIAL`$`D.8.1:Is a Placebo used in this Trial?`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`D.8.3:Pharmaceutical form of the placebo`
      [[1]]$`P. END OF TRIAL`$`D.8.3:Pharmaceutical form of the placebo`[[1]]
      [1] "Solution for injection in pre-filled syringe"
      
      
      [[1]]$`P. END OF TRIAL`$`D.8.4:Route of administration of the placebo`
      [[1]]$`P. END OF TRIAL`$`D.8.4:Route of administration of the placebo`[[1]]
      [1] "Subcutaneous use"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.1:Medical condition(s) being investigated`
      [[1]]$`P. END OF TRIAL`$`E.1.1:Medical condition(s) being investigated`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.1.1:Medical condition in easily understood language`
      [[1]]$`P. END OF TRIAL`$`E.1.1.1:Medical condition in easily understood language`[[1]]
      [1] "Bilateral nasal polyposis"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.1.2:Therapeutic area`
      [[1]]$`P. END OF TRIAL`$`E.1.1.2:Therapeutic area`[[1]]
      [1] "Diseases [C] - Ear, nose and throat diseases [C09]"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.2:Version`
      [[1]]$`P. END OF TRIAL`$`E.1.2:Version`[[1]]
      [1] "19.0"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.2:Level`
      [[1]]$`P. END OF TRIAL`$`E.1.2:Level`[[1]]
      [1] "PT"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.2:Classification code`
      [[1]]$`P. END OF TRIAL`$`E.1.2:Classification code`[[1]]
      [1] "10028756"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.2:Term`
      [[1]]$`P. END OF TRIAL`$`E.1.2:Term`[[1]]
      [1] "Nasal polyps"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.2:System Organ Class`
      [[1]]$`P. END OF TRIAL`$`E.1.2:System Organ Class`[[1]]
      [1] "10038738 - Respiratory, thoracic and mediastinal disorders"
      
      
      [[1]]$`P. END OF TRIAL`$`E.1.3:Condition being studied is a rare disease`
      [[1]]$`P. END OF TRIAL`$`E.1.3:Condition being studied is a rare disease`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.2.1:Main objective of the trial`
      [[1]]$`P. END OF TRIAL`$`E.2.1:Main objective of the trial`[[1]]
      [1] "To evaluate the efficacy of dupilumab compared to placebo on a background of mometasone furoate nasal spray (MFNS) in reducing nasal congestion/obstruction (NC) severity and endoscopic nasal polyposis score (NPS) in patients with bilateral nasal polyposis (NP). In addition for Japan, reduction in computed tomography (CT) scan opacification of the sinuses will be also a coprimary objective."
      
      
      [[1]]$`P. END OF TRIAL`$`E.2.2:Secondary objectives of the trial`
      [[1]]$`P. END OF TRIAL`$`E.2.2:Secondary objectives of the trial`[[1]]
      [1] "-To evaluate the efficacy of dupilumab in improving total symptoms score (TSS).\r-To evaluate the efficacy of dupilumab in improving sense of smell.\r-To evaluate the efficacy of dupilumab in reducing CT scan opacification of the sinuses (Primary objective for Japan).\r-To evaluate ability of dupilumab in reducing proportion of patients requiring treatment with oral corticosteroids or NP surgery.\r-To evaluate the effect of dupilumab on patient reported outcomes and health related quality of life outcome by sinonasal outcome test-22 (SNOT-22).\r-To evaluate efficacy with various regimen.\r-To evaluate the effect of dupilumab in the subgroups of patients with prior surgery and co-morbid asthma (including non-steroid antiinflammatory drug [NSAID] exacerbated respiratory disease NERD]).\r-To evaluate the safety of dupilumab in patients with bilateral NP.\r-To evaluate functional dupilumab concentrations (systemic exposure) and incidence of treatmentemergent anti-drug antibodies (ADA)."
      
      
      [[1]]$`P. END OF TRIAL`$`E.2.3:Trial contains a sub-study`
      [[1]]$`P. END OF TRIAL`$`E.2.3:Trial contains a sub-study`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.3:Principal inclusion criteria`
      [[1]]$`P. END OF TRIAL`$`E.3:Principal inclusion criteria`[[1]]
      [1] "-Patients with bilateral sinonasal polyposis that despite prior treatment with systemic corticosteroids (SCS) anytime within the past 2 years; and/or have a medical contraindication/intolerance to SCS, and/or had prior surgery for NP at the screening visit, have:\r \r\n   -An endoscopic bilateral NPS of at least 5 out of a maximum score of 8 (with a minimum score of 2 in each nasal cavity).\r\r\n    -Ongoing symptoms (for at least 8 weeks before V1) of nasal congestion/ blockage/obstruction with moderate or severe symptom severity (score 2 or 3) at V1 and a weekly average severity of greater than 1 at time of randomization (V2), and another symptom such as loss of smell, rhinorrhea (anterior/posterior).\r\r\n-Signed written informed consent."
      
      
      [[1]]$`P. END OF TRIAL`$`E.4:Principal exclusion criteria`
      [[1]]$`P. END OF TRIAL`$`E.4:Principal exclusion criteria`[[1]]
      [1] "- Patients <18 years of age.\r\r\n- Patient who has been previously treated in dupilumab studies.\r\r\n- Patient who has taken:\r\r\n     -Biologic therapy/ systemic immunosuppressant to treat inflammatory disease or autoimmune disease (eg, rheumatoid arthritis, inflammatory bowel disease, primary biliary cirrhosis, systemic lupus erythematosus, multiple sclerosis, etc.) within 2 months before V1 or 5 half-lives, whichever is longer.\r     \r\n     -Any experimental monoclonal antibody (mAB) within 5 half-lives or within 6 months before V1 if the half-life is unknown.\r\r\n     -Anti-immunoglobulin E therapy (omalizumab) within 130 days prior to V1.\r\r\n     -Leukotriene antagonists/modifiers unless patient is on a continuous treatment for at least 30 days prior to V1.\r\r\n- Initiation of allergen immunotherapy within 3 months prior to V1 or a plan to begin therapy or change its dose during the run-in period or the randomized treatment period.\r\r\n- Patients who have undergone any intranasal and/or sinus surgery (including polypectomy) within 6 months before V1.\r\r\n- Patients who have had a sinonasal or sinus surgery changing the lateral wall structure of the nose making impossible the evaluation of NPS.\r\r\n- Patients with conditions/concomitant diseases making them non evaluable at V1 or for the primary\refficacy endpoint such as:\r     \r\n     -Antrochoanal polyps,\r\r\n     -Nasal septal deviation that would occlude at least one nostril,\r\r\n     -Acute sinusitis, nasal infection or upper respiratory infection,\r\r\n     -Ongoing rhinitis medicamentosa,\r\r\n     -Allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener’s granulomatosis),Young’s syndrome, Kartagener’s syndrome or other dyskinetic ciliary\rsyndromes, concomitant cystic fibrosis,\r\r\n     -Radiologic suspicion, or confirmed invasive or expansive fungal rhinosinusitis.\r\r\n- Patients with nasal cavity malignant tumor and benign tumors (eg, papilloma, blood boil etc.).\r\r\n- Patients with forced expiratory volume (FEV1) 50% or less (of predicted normal).\r\r\n- Patients receiving concomitant treatment prohibited in the study.\r\r\n- Treatment with a live (attenuated) vaccine within 12 weeks before the baseline visit.\r\r\n- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening.\r\r\n- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit.\r\r\n- Active chronic or acute infection requiring systemic treatment within 2 weeks before the Baseline visit.\r\r\n- Known or suspected history of immunosuppression.\r\r\n- Pregnant or breastfeeding women, or women planning to become pregnant or breastfeed during the study.\r\r\n- Women unwilling to use adequate birth control, if of reproductive potential and sexually active.\r\r\nNote: The information listed above is not intended to contain all considerations relevant to a patient's potential participation in this clinical trial therefore not all inclusion/ exclusion criteria are listed."
      
      
      [[1]]$`P. END OF TRIAL`$`E.5.1:Primary end point(s)`
      [[1]]$`P. END OF TRIAL`$`E.5.1:Primary end point(s)`[[1]]
      [1] "1- Change from baseline in NC symptom severity score based on\rthe patient daily morning assessment\r\r\n2- Change from baseline in NPS as assessed by nasal endoscopy\r\r\n3- Change from baseline in sinus opacifications as assessed by CT\rscans using Lund Mackay Score (For Japan only)"
      
      
      [[1]]$`P. END OF TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`P. END OF TRIAL`$`E.5.1.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3 : From baseline to Week 24"
      
      
      [[1]]$`P. END OF TRIAL`$`E.5.2:Secondary end point(s)`
      [[1]]$`P. END OF TRIAL`$`E.5.2:Secondary end point(s)`[[1]]
      [1] "1- Change from baseline in TSS\r\r\n2- Change from baseline in University of Pennsylvania Smell\rIdentification Test\r\r\n3- Change from baseline in severity of decreased/ loss of smell as\rassessed by the patient\r\r\n4- Change from baseline in sinus opacifications as assessed by CT scans using Lund Mackay Score (This endpoint will not be assessed as a secondary endpoint for Japan as it is already a co-primary endpoint).\r\r\n5- Change from baseline in in sinonasal outcome test-22 (SNOT-22)\r\r\n6- Proportion of patients during study treatment receiving oral corticosteroid (OCS) for NP and/or planned to under surgery for nasal polyps\r\r\n7- Change from baseline in NC for q2w (Arm A) versus placebo (Arm C)\r\r\n8- Change from baseline in NPS for q2w (Arm A) versus placebo (Arm C)\r\r\n9- Change from baseline in NC for q2w/q4w (Arm B) versus placebo (Arm C)\r\r\n10- Change from baseline in NPS for q2w/q4w (Arm B) versus placebo (Arm C)"
      
      
      [[1]]$`P. END OF TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`
      [[1]]$`P. END OF TRIAL`$`E.5.2.1:Timepoint(s) of evaluation of this end point`[[1]]
      [1] "1-2-3-4-5 : From baseline to Week 24\r\r\n6: 52 weeks\r\r\n7-8-9-10 : From baseline to Week 52"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.1:Diagnosis`
      [[1]]$`P. END OF TRIAL`$`E.6.1:Diagnosis`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.2:Prophylaxis`
      [[1]]$`P. END OF TRIAL`$`E.6.2:Prophylaxis`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.3:Therapy`
      [[1]]$`P. END OF TRIAL`$`E.6.3:Therapy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.4:Safety`
      [[1]]$`P. END OF TRIAL`$`E.6.4:Safety`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.5:Efficacy`
      [[1]]$`P. END OF TRIAL`$`E.6.5:Efficacy`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.6:Pharmacokinetic`
      [[1]]$`P. END OF TRIAL`$`E.6.6:Pharmacokinetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.7:Pharmacodynamic`
      [[1]]$`P. END OF TRIAL`$`E.6.7:Pharmacodynamic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.8:Bioequivalence`
      [[1]]$`P. END OF TRIAL`$`E.6.8:Bioequivalence`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.9:Dose response`
      [[1]]$`P. END OF TRIAL`$`E.6.9:Dose response`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.10:Pharmacogenetic`
      [[1]]$`P. END OF TRIAL`$`E.6.10:Pharmacogenetic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.11:Pharmacogenomic`
      [[1]]$`P. END OF TRIAL`$`E.6.11:Pharmacogenomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.12:Pharmacoeconomic`
      [[1]]$`P. END OF TRIAL`$`E.6.12:Pharmacoeconomic`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.6.13:Others`
      [[1]]$`P. END OF TRIAL`$`E.6.13:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.1:Human pharmacology (Phase I)`
      [[1]]$`P. END OF TRIAL`$`E.7.1:Human pharmacology (Phase I)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.1.1:First administration to humans`
      [[1]]$`P. END OF TRIAL`$`E.7.1.1:First administration to humans`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.1.2:Bioequivalence study`
      [[1]]$`P. END OF TRIAL`$`E.7.1.2:Bioequivalence study`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.1.3:Other`
      [[1]]$`P. END OF TRIAL`$`E.7.1.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.1.3.1:Other trial type description`
      [[1]]$`P. END OF TRIAL`$`E.7.1.3.1:Other trial type description`[[1]]
      [1] ""
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`
      [[1]]$`P. END OF TRIAL`$`E.7.2:Therapeutic exploratory (Phase II)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`
      [[1]]$`P. END OF TRIAL`$`E.7.3:Therapeutic confirmatory (Phase III)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.7.4:Therapeutic use (Phase IV)`
      [[1]]$`P. END OF TRIAL`$`E.7.4:Therapeutic use (Phase IV)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1:Controlled`
      [[1]]$`P. END OF TRIAL`$`E.8.1:Controlled`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.1:Randomised`
      [[1]]$`P. END OF TRIAL`$`E.8.1.1:Randomised`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.2:Open`
      [[1]]$`P. END OF TRIAL`$`E.8.1.2:Open`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.3:Single blind`
      [[1]]$`P. END OF TRIAL`$`E.8.1.3:Single blind`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.4:Double blind`
      [[1]]$`P. END OF TRIAL`$`E.8.1.4:Double blind`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.5:Parallel group`
      [[1]]$`P. END OF TRIAL`$`E.8.1.5:Parallel group`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.6:Cross over`
      [[1]]$`P. END OF TRIAL`$`E.8.1.6:Cross over`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.1.7:Other`
      [[1]]$`P. END OF TRIAL`$`E.8.1.7:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.2.1:Other medicinal product(s)`
      [[1]]$`P. END OF TRIAL`$`E.8.2.1:Other medicinal product(s)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.2.2:Placebo`
      [[1]]$`P. END OF TRIAL`$`E.8.2.2:Placebo`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.2.3:Other`
      [[1]]$`P. END OF TRIAL`$`E.8.2.3:Other`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.2.4:Number of treatment arms in the trial`
      [[1]]$`P. END OF TRIAL`$`E.8.2.4:Number of treatment arms in the trial`[[1]]
      [1] "3"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`
      [[1]]$`P. END OF TRIAL`$`E.8.3:The trial involves single site in the Member State concerned`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`
      [[1]]$`P. END OF TRIAL`$`E.8.4:The trial involves multiple sites in the Member State concerned`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`
      [[1]]$`P. END OF TRIAL`$`E.8.4.1:Number of sites anticipated in Member State concerned`[[1]]
      [1] "3"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.5:The trial involves multiple Member States`
      [[1]]$`P. END OF TRIAL`$`E.8.5:The trial involves multiple Member States`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`
      [[1]]$`P. END OF TRIAL`$`E.8.5.1:Number of sites anticipated in the EEA`[[1]]
      [1] "18"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`
      [[1]]$`P. END OF TRIAL`$`E.8.6.1:Trial being conducted both within and outside the EEA`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`
      [[1]]$`P. END OF TRIAL`$`E.8.6.2:Trial being conducted completely outside of the EEA`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`
      [[1]]$`P. END OF TRIAL`$`E.8.6.3:If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned`[[1]]
      [1] "Argentina\nAustralia\nBelgium\nCanada\nChile\nIsrael\nJapan\nMexico\nPortugal\nRussian Federation\nSpain\nSweden\nTurkey\nUnited States"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.7:Trial has a data monitoring committee`
      [[1]]$`P. END OF TRIAL`$`E.8.7:Trial has a data monitoring committee`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`
      [[1]]$`P. END OF TRIAL`$`E.8.8:Definition of the end of the trial and justification where it is not the last\n                        visit of the last subject undergoing the trial`[[1]]
      [1] "LVLS"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned years`
      [[1]]$`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned years`[[1]]
      [1] "1"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned months`
      [[1]]$`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned months`[[1]]
      [1] "10"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned days`
      [[1]]$`P. END OF TRIAL`$`E.8.9.1:In the Member State concerned days`[[1]]
      [1] "0"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial years`
      [[1]]$`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial years`[[1]]
      [1] "2"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial months`
      [[1]]$`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial months`[[1]]
      [1] "1"
      
      
      [[1]]$`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial days`
      [[1]]$`P. END OF TRIAL`$`E.8.9.2:In all countries concerned by the trial days`[[1]]
      [1] "0"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1:Trial has subjects under 18`
      [[1]]$`P. END OF TRIAL`$`F.1.1:Trial has subjects under 18`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1.1:In Utero`
      [[1]]$`P. END OF TRIAL`$`F.1.1.1:In Utero`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`
      [[1]]$`P. END OF TRIAL`$`F.1.1.2:Preterm newborn infants (up to gestational age < 37 weeks)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1.3:Newborns (0-27 days)`
      [[1]]$`P. END OF TRIAL`$`F.1.1.3:Newborns (0-27 days)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`
      [[1]]$`P. END OF TRIAL`$`F.1.1.4:Infants and toddlers (28 days-23 months)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1.5:Children (2-11years)`
      [[1]]$`P. END OF TRIAL`$`F.1.1.5:Children (2-11years)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.1.6:Adolescents (12-17 years)`
      [[1]]$`P. END OF TRIAL`$`F.1.1.6:Adolescents (12-17 years)`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.2:Adults (18-64 years)`
      [[1]]$`P. END OF TRIAL`$`F.1.2:Adults (18-64 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.2.1:Number of subjects for this age range:`
      [[1]]$`P. END OF TRIAL`$`F.1.2.1:Number of subjects for this age range:`[[1]]
      [1] "655"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.3:Elderly (>=65 years)`
      [[1]]$`P. END OF TRIAL`$`F.1.3:Elderly (>=65 years)`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.1.3.1:Number of subjects for this age range:`
      [[1]]$`P. END OF TRIAL`$`F.1.3.1:Number of subjects for this age range:`[[1]]
      [1] "65"
      
      
      [[1]]$`P. END OF TRIAL`$`F.2.1:Female`
      [[1]]$`P. END OF TRIAL`$`F.2.1:Female`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.2.2:Male`
      [[1]]$`P. END OF TRIAL`$`F.2.2:Male`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.1:Healthy volunteers`
      [[1]]$`P. END OF TRIAL`$`F.3.1:Healthy volunteers`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.2:Patients`
      [[1]]$`P. END OF TRIAL`$`F.3.2:Patients`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3:Specific vulnerable populations`
      [[1]]$`P. END OF TRIAL`$`F.3.3:Specific vulnerable populations`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`
      [[1]]$`P. END OF TRIAL`$`F.3.3.1:Women of childbearing potential not using contraception`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`
      [[1]]$`P. END OF TRIAL`$`F.3.3.2:Women of child-bearing potential using contraception`[[1]]
      [1] "Yes"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.3:Pregnant women`
      [[1]]$`P. END OF TRIAL`$`F.3.3.3:Pregnant women`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.4:Nursing women`
      [[1]]$`P. END OF TRIAL`$`F.3.3.4:Nursing women`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.5:Emergency situation`
      [[1]]$`P. END OF TRIAL`$`F.3.3.5:Emergency situation`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`
      [[1]]$`P. END OF TRIAL`$`F.3.3.6:Subjects incapable of giving consent personally`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.3.3.7:Others`
      [[1]]$`P. END OF TRIAL`$`F.3.3.7:Others`[[1]]
      [1] "No"
      
      
      [[1]]$`P. END OF TRIAL`$`F.4.1:In the member state`
      [[1]]$`P. END OF TRIAL`$`F.4.1:In the member state`[[1]]
      [1] "9"
      
      
      [[1]]$`P. END OF TRIAL`$`F.4.2.1:In the EEA`
      [[1]]$`P. END OF TRIAL`$`F.4.2.1:In the EEA`[[1]]
      [1] "72"
      
      
      [[1]]$`P. END OF TRIAL`$`F.4.2.2:In the whole clinical trial`
      [[1]]$`P. END OF TRIAL`$`F.4.2.2:In the whole clinical trial`[[1]]
      [1] "720"
      
      
      [[1]]$`P. END OF TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`
      [[1]]$`P. END OF TRIAL`$`F.5:Plans for treatment or care after the subject has ended the participation in the trial\n                            (if it is different from the expected normal treatment of that condition)`[[1]]
      [1] "None"
      
      
      [[1]]$`P. END OF TRIAL`$`N.:Competent Authority Decision`
      [[1]]$`P. END OF TRIAL`$`N.:Competent Authority Decision`[[1]]
      [1] "Authorised"
      
      
      [[1]]$`P. END OF TRIAL`$`N.:Date of Competent Authority Decision`
      [[1]]$`P. END OF TRIAL`$`N.:Date of Competent Authority Decision`[[1]]
      [1] "2016-11-03"
      
      
      [[1]]$`P. END OF TRIAL`$`N.:Ethics Committee Opinion of the trial application`
      [[1]]$`P. END OF TRIAL`$`N.:Ethics Committee Opinion of the trial application`[[1]]
      [1] "Favourable"
      
      
      [[1]]$`P. END OF TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`
      [[1]]$`P. END OF TRIAL`$`N.:Ethics Committee Opinion: Reason(s) for unfavourable opinion`[[1]]
      [1] ""
      
      
      [[1]]$`P. END OF TRIAL`$`N.:Date of Ethics Committee Opinion`
      [[1]]$`P. END OF TRIAL`$`N.:Date of Ethics Committee Opinion`[[1]]
      [1] "2016-11-29"
      
      
      [[1]]$`P. END OF TRIAL`$`P.:End of Trial Status`
      [[1]]$`P. END OF TRIAL`$`P.:End of Trial Status`[[1]]
      [1] "Completed"
      
      
      
      

